Selectable eccentric remodeling and/or ablation

Description

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable

REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK

Not Applicable

BACKGROUND OF THE INVENTION
1. Field of the Invention

The present invention is generally related to medical devices, systems, and methods. In an exemplary embodiment, the invention provides catheter-based remodeling and/or removal of atherosclerosis plaque built-up in an artery to improve blood flow, often without balloon angioplasty, stenting, and/or dilation. The structures of the invention allow image-guided eccentric atherosclerotic material remodeling and/or removal typically using electrosurgical energy, optionally using electrosurgical ablation, often in a controlled environment zone within the blood vessel, and ideally with a co-located intravascular imaging capability. Related embodiments have applications in a variety of body lumens, including urinary, reproductive, gastrointestinal, and pulmonary obstructive material removal, optionally for removing or decreasing tumors, cysts, polyps, and the like.

Physicians use catheters to gain access to and repair interior tissues of the body, particularly within the lumens of the body such as blood vessels. For example, balloon angioplasty and other catheters often are used to open arteries that have been narrowed due to atherosclerotic disease.

Balloon angioplasty is often effective at opening an occluded blood vessel, but the trauma associated with balloon dilation can impose significant injury, so that the benefits of balloon dilation may be limited in time. Stents are commonly used to extend the beneficial opening of the blood vessel.

Stenting, in conjunction with balloon dilation, is often the preferred treatment for atherosclerosis. In stenting, a collapsed metal framework is mounted on a balloon catheter which is introduced into the body. The stent is manipulated into the site of occlusion and expanded in place by the dilation of the underlying balloon. Stenting has gained widespread acceptance, and produces generally acceptable results in many cases. Along with treatment of blood vessels (particularly the coronary arteries), stents can also be used in treating many other tubular obstructions within the body, such as for treatment of reproductive, gastrointestinal, and pulmonary obstructions.

Restenosis or a subsequent narrowing of the body lumen after stenting has occurred in a significant number of cases. More recently, drug coated stents (such as Johnson and Johnson's Cypher™ stent, the associated drug comprising Sirolimus™) have demonstrated a markedly reduced restenosis rate, and others are developing and commercializing alternative drug eluting stents. In addition, work has also been initiated with systemic drug delivery (intravenous or oral) which may also improve the procedural angioplasty success rates.

While drug eluting stents appear to offer significant promise for treatment of atherosclerosis in many patients, there remain many cases where stents either cannot be used or present significant disadvantages. Generally, stenting leaves an implant in the body. Such implants can present risks, including mechanical fatigue, corrosion, and the like, particularly when removal of the implant is difficult and involves invasive surgery. Stenting may have additional disadvantages for treating diffuse artery disease, for treating bifurcations, for treating areas of the body susceptible to crush, and for treating arteries subject to torsion, elongation, and shortening.

A variety of modified restenosis treatments or restenosis-inhibiting occlusion treatment modalities have also been proposed, including intravascular radiation, cryogenic treatments, ultrasound energy, and the like, often in combination with balloon angioplasty and/or stenting. While these and different approaches show varying degrees of promise for decreasing the subsequent degradation in blood flow following angioplasty and stenting, the trauma initially imposed on the tissues by angioplasty remains problematic.

A number of alternatives to stenting and balloon angioplasty so as to open stenosed arteries have also been proposed. For example, a wide variety of atherectomy devices and techniques have been disclosed and attempted. Despite the disadvantages and limitations of angioplasty and stenting, atherectomy has not gained the widespread use and success rates of dilation-based approaches. Still further disadvantages of dilation have come to light. These include the existence of vulnerable plaque, which can rupture and release materials that may cause myocardial infarction or heart attack.

In light of the above, it would be advantageous to provide new devices, systems, and methods for remodeling and/or removal of atherosclerotic material and other occlusions of the lumens of the body, and particularly from blood vessels. It would further be desirable to enable the removal of these occlusive materials without having to resort to the trauma of a dilation, and to allow the opening of blood vessels and other body lumens which are not suitable for stenting.

BRIEF SUMMARY OF THE INVENTION

In a first non-limiting embodiment, there is a catheter system for eccentric remodeling of atherosclerotic material of a blood vessel of a patient. The system comprises an elongate flexible catheter body having a proximal end and a distal end with an axis therebetween. A radially expandable structure is disposed near the end of the catheter body, and a plurality of energy delivery surfaces are each oriented radially when the expandable structure expands. An atherosclerotic material detector is disposed for circumferential atherosclerotic material detection. A power source is electrically coupled to the energy delivery surfaces. The power source energizes the energy delivery surfaces so as to eccentrically remodel the detected atherosclerotic material.

The power source will often selectively energize a subset of the energy delivery surfaces so as to effect eccentric remodeling. The catheter body may have a lumen extending between the proximal and distal ends, and an aspiration connector may be in fluid communication with the lumen at the proximal end of the catheter body. Proximal and distal debris barriers may be disposed proximally and distally of the energy delivery surfaces, respectively, and an aspiration port may be disposed between the proximal and distal barriers for removal of debris during atherosclerotic material remodeling.

The atherosclerotic material detector may include an intravascular ultrasound catheter disposed in the lumen of the catheter body, an intravascular optical coherence tomography catheter disposed in the lumen, an intravascular catheter having an MRI antenna disposed in the lumen, or the like. Alternative detectors may employ any of a variety of non-invasive imaging modalities, including external systems making use of X-rays, CT systems, non-invasive MRI or NMR systems, or the like, so that the detector may not be disposed in the blood vessel. In some embodiments, a brachytherapy catheter or other restenosis inhibitor may be advanced distally within the lumen.

The radially expandable body may comprise a plurality of flexible struts, and the energy delivery surfaces may define a circumferentially oriented array, with the energy delivery surfaces often comprising electrodes or microwave antennas. Struts of the radially expandable structure may have perforations disposed therebetween so as to define an expandable basket. The basket may have proximal and distal portions with intermediate portion disposed therebetween. The array of electrodes may be supported along the intermediate portion so as to engage adjacent atherosclerotic material when the basket is expanded within the blood vessel. The electrodes may comprise conductive surfaces of an electrode structure mounted to a separately formed basket strut. In other embodiments, electrode surfaces may be formed as part of the expandable structure. For example, the electrodes may comprise a localized widening of an associated strut, often disposed near center of a length of the strut. The expandable structure may comprise Nitinol™, and the remaining surface of the Nitinol strut may be insulated. For example, the surface may be coated with a high temperature polymer (such as a polyimide or the like). Other coatings may alternatively be used, including polyurethane. The struts may be electrically insulated from each other, so that each strut can be used to conduct energy to an electrode surface associated with the strut from a conductor extending proximally from the strut so as to independently couple each electrode surface to a controller.

A distal membrane may be deployable within the blood vessel distally of the electrode so as to inhibit distal movement of debris. A proximal membrane may be deployable proximally of the electrode so as to inhibit proximal movement of the debris. The membranes may inhibit blood interaction with the remodeling process, for example, during ablation of the atherosclerotic material. In other embodiments, power supplied to the energy delivery surfaces may be limited so as to inhibit debris generation, for example, by denaturing the atherosclerotic material, by melting of atherosclerotic material inside layers of the artery, by shrinking of atherosclerotic material inside layers of the artery (during treatment and/or in a tissue healing response), and the like. In some embodiments, the distal membrane may be supported by the distal portion of the basket so as to expand radially therewith. The proximal membrane may be supported by the proximal portion of the basket so as to expand radially therewith. At least one of the proximal and distal membranes may comprise a lumen axially off-set from the basket.

While some embodiments may have a single monopolar electrode or two or more monopolar or bipolar electrodes, the electrodes may comprise an array of at least three alternatively selectable electrodes distributed circumferentially about the axis, often comprising six or more electrodes. A controller may couple the power source to the electrode array so as to selectively energize that eccentric subset of the electrode array in response to the detected atherosclerotic material. A controller may selectively energize a subset of the energy directing surfaces by directing RF energy and/or microwave energy thereto. The atherosclerotic material detector may comprise an ultrasound transducer or optical coherence reflectrometer. Along with stand-alone structures that are insertable into a lumen of the catheter, these detectors may also be integrated into the catheter structure. A display may be coupled to the atherosclerotic material detector to show an image of circumferential atherosclerotic material thickness distributed about the catheter axis.

In another non-limiting embodiment, there is a catheter system for eccentric remodeling and/or removal of atherosclerotic material from a blood vessel of a patient. The system comprises an elongate flexible catheter body having a proximal end and a distal end with an axis therebetween. A radially expandable structure is disposed near the distal end of the catheter body. A plurality of electrodes are oriented to be radially urged against atherosclerotic material when the expandable structure expands. An atherosclerotic material detector or imaging sensor is disposed near the distal end of the catheter body for circumferential identification and measurement of atherosclerotic material. A power source is electrically coupled to the electrodes. The power source energizes the electrodes so as to eccentrically remove and/or ablate the measured atherosclerotic material.

The catheter body will often have a lumen extending between the proximal end and the distal end. The lumen may be used as an aspiration lumen, for example, using an aspiration source in fluid communication with the lumen at the proximal end of the catheter body. Proximal and distal ablation debris barriers may be disposed proximally and distally of the electrodes, respectively, with an aspiration port disposed between the proximal and distal barriers for removal of ablation debris during atherosclerotic material ablation. The atherosclerotic material detector may comprise an ultrasound transducer of an intravascular ultrasound catheter, with the intravascular ultrasound catheter disposed in the lumen. Alternatively, other imaging modalities may be employed, including intravascular optical coherence tomography. Imaging or atherosclerotic material detecting capabilities might also be incorporated into the catheter body in some embodiments, with circumferential atherosclerotic thicknesses often being measured. An irrigation lumen may extend between the proximal end of the catheter body and the distal end of the catheter body, facilitating an enhanced local ablation environment adjacent the electrodes. A restenosis inhibitor may be advanced within the lumen, the restenosis inhibitor optionally comprising an intravascular radiation catheter, restenosis inhibiting drugs, or the like.

The radially expandable body may comprise a plurality of flexible members or struts, the electrodes optionally defining a circumferential electrode array. The struts may have perforations or openings therebetween so as to define an expandable basket. The array of electrodes may be supported along an intermediate portion of the basket and oriented radially so as to engage adjacent atherosclerotic material when the basket is expanded within a blood vessel. An aspiration port in fluid communication with an interior of the basket may facilitate removal of any ablation debris and tissue vaporization gasses, and may inhibit release of these byproducts of ablation within the blood vessel, and fluid flowing within the basket may act as a cooling fluid to limit collateral tissue damage. A distal membrane or barrier deployable within the blood vessel distally of the electrodes may inhibit distal movement of any ablation debris, while a proximal membrane or membrane deployable proximally of the electrodes may inhibit proximal movement of any ablation debris. Such member(s) may also reduce or inhibit blood flow within a localized remodeling and/or ablation environment. The distal membrane may be supported by the distal portion of the basket so as to expand radially therewith, and/or the proximal membrane may be supported by the proximal portion of the basket so as to expand radially therewith. Suitable membranes include, for example, one or more balloons axially offset from the basket within the blood vessel, or a braided superelastic material such as Nitinol™ dipped in silicone, polyurethane, PTFE, or another elastic material. In some embodiments, the membrane may be at least in part integrated with the basket.

The electrodes will often comprise an array of at least three, often comprising at least six alternatively selectable electrodes distributed circumferentially about the axis of the catheter body. The arrays of electrodes may be axisymmetric, with an eccentric treatment orientation being selected without physically rotating the array by selectively pairing electrodes of the array. A controller couples the power source to the electrode array for selectively energizing an eccentric subset of the electrode array in response to the measured atherosclerotic material. Exemplary electrodes may comprise stainless steel soldered to copper wires, with the copper wires insulated from supporting elements of associated expandable basket elements. Alternative electrodes may comprise platinum (which also allows the electrode to serve as a radiopaque marker). The electrode/basket assembly may be, for example, coated with a high temperature polymer, such as a polyimide. An exemplary electrode array includes alternating axially offset electrodes, and the controller will often direct RF bipolar power between pairs of the energized subset of electrodes, the pairs optionally comprising circumferentially offset electrodes, adjacent axially aligned electrodes, or alternating between axially and circumferentially offset electrodes. In some embodiments monopolar energy may be directed to selected electrodes, with the circuit being completed by a patient ground. More generally, each electrode will typically comprise a metallic body affixed to an adjacent strut of the expandable structure by a polymer with an associated conductor extending proximally from the electrode so as to electrically couple the electrode surface to the controller.

One exemplary atherosclerotic material detector may include an ultrasound transducer of an intravascular ultrasound catheter, a sensor of an intravascular optical coherence tomography catheter, or the like. A display may be provided to show an image of circumferential sclerotic material thickness about the catheter axis, the display and/or imaging catheter signals optionally comprising indicia of orientation for rotationally registering the selected electrodes to the measurements. Suitable indicia may comprise a “key” or distinguishable image of at least one expandable member or marker.

In another non-limiting embodiment, there is a catheter for atherosclerotic material removal from the blood vessel of a patient. The catheter comprises an elongate flexible catheter body having a proximal end and a distal end with an axial aspiration lumen therebetween. A radially expandable basket near the distal end of the catheter body has a proximal portion and a distal portion with an intermediate portion disposed therebetween. A circumferential electrode array is distributed about the intermediate portion of the radially expandable basket so as to ablate adjacent atherosclerotic material when the basket expands within the blood vessel. An aspiration port provides fluid communication between the aspiration lumen and an interior of the basket. A distal membrane supported by the distal portion of the basket inhibits distal movement of ablation debris when the basket is expanded within the blood vessel. A proximal membrane supported by the proximal portion of the basket inhibits proximal movement of ablation debris when the basket is expanded within the blood vessel.

One non-limiting embodiment of a method is a method for remodeling eccentric atherosclerotic material of a blood vessel of a patient. The method comprises positioning a working end of a catheter within the blood vessel adjacent the atherosclerotic material, the catheter defining an axis. The catheter is radially expanded so as to engage at least one energy delivery surface of the catheter against the atherosclerotic material. A circumferential distribution of the atherosclerotic material about the axis of the catheter is determined. Electrosurgical energy is directed from the at least one energy delivery surface eccentrically relative to the axis of the catheter in response to the determined atherosclerotic material distribution.

Remodeling of the atherosclerotic material may comprise ablation, removal, shrinkage, melting, denaturing, and/or the like of the atherosclerotic material. For example, relatively low power RF energy may be used to heat the atherosclerotic material until it melts, the material optionally being redistributed along the artery wall, inside layers of the vessel, or the like. Optionally, the atherosclerotic material may comprise a vulnerable plaque. Vulnerable plaques (and/or blood vessels in which vulnerable plaque is a concern) may be treated using RF energy to mildly heat the cap and underlying lipid-rich pool of the vulnerable plaque to a temperature in a range from about 50 to about 60° Celsius. This may be performed so as to generate thickening of the cap, often as an immune response to heating. Such thickening may potentially result in restenosis, and cap thickening and/or restenosis may be limited by accurate control of the RF energy, the use of anti-restenotic drugs (such as Rapamycin™ or the like). In addition to vulnerable plaque stabilization, the invention may be employed to eliminate vulnerable plaques, optionally by heating of the lipid-rich pool to a temperature of at least around 90° Celsius. Preferably, heating of the blood vessel will be performed so as to limit a temperature of an adventitia or outer layer of the blood vessel to below about 63° Celsius so as to inhibit collagen shrinkage and vessel collapse. In contrast, mild RF energy may be applied to the atherosclerotic material so as to denature the material and result in shrinkage of the material during or after treatment. Shrinkage of atherosclerotic material may lead to larger open vessel lumens and improved blood flow.

When remodeling of atherosclerotic plaques comprises ablation of atherosclerotic materials, any thrombolitic debris generated may be restrained and/or evacuated. Where ablation generates non-thrombolitic debris, or where remodeling is performed so as to inhibit debris generation, debris restraining and evacuation may be unnecessary.

Electrosurgical energy directed by the one or more energy delivery surfaces will often comprise RF and/or microwave electrical energy. The circumferential distribution of atherosclerotic material may be determined using intravascular or non-invasive techniques. The electrosurgical energy may be directed eccentrically without rotating the energy delivery surfaces about the catheter axis by energizing a subset of the electrodes. The subset of electrodes may be selected in response to the determined atherosclerotic material distribution. Selected electrodes may be rotationally registered with the atherosclerotic material distribution, for example, with reference to one or more structures of the expandable basket having a distinguishable image. For example, a strut of the electrode arbitrarily identified as electrode 1 may have one radiopaque marker or other distinguishable image, and a strut of an electrode referenced as electrode 2 may have two radiopaque markers or two distinguishable image features. This can help identify all of the electrodes, since electrode 1 is identifiable and the direction from electrode 1 to electrode 2 indicates a circumferential electrode count direction. A variety of alternative distinguishable features with integrated or separate circumferential electrode count orientation indicators may also be utilized. In some embodiments, registration may be performed automatically with reference to an electronic signal.

In yet another non-limiting embodiment, there is a method for eccentric atherosclerotic material removal from a blood vessel of a patient. The method comprises positioning a working end of the catheter within the blood vessel and adjacent the atherosclerotic material. The catheter defines the axis. The catheter is radially expanded so as to engage a plurality of electrodes of the catheter against the atherosclerotic material. A circumferential distribution of the atherosclerotic material is measured about the axis of the catheter. RF energy is directed from the electrodes eccentrically relative to the axis of the catheter in response to the measured atherosclerotic material distribution.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A illustrates diffuse atherosclerotic disease in which a substantial length of multiple blood vessels has limited effective diameters.

FIG. 1B illustrates vulnerable plaque within a blood vessel.

FIG. 1C illustrates the sharp bends or tortuosity of some blood vessels.

FIG. 1D illustrates atherosclerotic disease at a bifurcation.

FIG. 1E illustrates a lesion associated with atherosclerotic disease of the extremities.

FIG. 1F is an illustration of a stent fracture or corrosion.

FIG. 1G illustrates a dissection within a blood vessel.

FIG. 1H illustrates a circumferential measurement of an artery wall around a healthy artery.

FIG. 1I illustrates circumferential distribution of atheroma about a restenosed artery.

FIG. 2 schematically illustrates an atherosclerotic material catheter system according to the present invention.

FIG. 2A schematically illustrates a catheter system for remodeling atherosclerotic material, the system including the catheter of FIG. 2.

FIG. 3 illustrates an expandable basket and an associated electrode array of the catheter system of FIG. 2.

FIGS. 4 and 5 illustrate alternative basket structures for use with the catheter system of FIG. 2.

FIGS. 6A and 6B illustrate an exemplary basket structure having alternating axially offset electrodes in a circumferential array.

FIGS. 7A and 7B illustrate an exemplary ablation debris barrier for use with a basket.

FIG. 7C illustrates an alternative basket and debris barrier.

FIG. 8 illustrates electrodes having dedicated conductors mounted to associated elements of a superelastic metal basket.

FIG. 9 is an illustration of a basket comprising polyimide supporting a circumferential array of electrodes.

FIGS. 10A-E illustrate an exemplary atherosclerotic material remodeling and/or removal method using the catheter system of FIG. 2.

FIGS. 11-21 schematically illustrate alternative catheters and catheter systems for use in the methods described herein.

FIGS. 22-25 schematically illustrate controllers for selectively energizing electrodes in the system of FIG. 2.

FIGS. 26 and 27 schematically illustrate alternative fluid flow paths for use in an atherosclerotic material remodeling catheter.

FIGS. 28A-28D illustrate an alternative controller for selectively energizing electrodes in the system of FIG. 2.

FIGS. 29A-29H illustrate an alternative basket structure formed with independent struts having a localized enhanced width for use as an electrode surface, along with components thereof.

FIGS. 30A and 30B schematically illustrate electrical circuitry allowing thermocouples and other temperature sensors to be used both for measuring temperature and as electrodes.

FIG. 31 schematically illustrates an alternative catheter structure for use in the methods described herein.

FIGS. 32A-32D schematically illustrate alternative basket and catheter structures for use in the methods described herein.

FIG. 33 schematically illustrates an alternative catheter structure using microwave energy to remodel atherosclerotic material.

FIG. 34 schematically illustrates an alternative catheter structure having lumens extending toward the electrodes so as to provide directed irrigation flow in the methods described herein.

FIG. 35 schematically illustrates a further alternative catheter basket structure having lumens for directing irrigation flow toward the microwave antennas for use in the methods described herein.

FIG. 36 is a schematic cross sectional view showing the application of different power levels through different electrodes so as to eccentrically remodel atherosclerotic materials.

FIGS. 37A-37C illustrate a further alternative catheter basket structure, in which the basket comprises polyimide for supporting a circumferential array of electrodes and facilitating intravascular imaging.

FIGS. 38A-38E are cross sectional side views through a body lumen showing additional aspects of treatment methods and devices described herein.

FIGS. 38F-38H are cross sectional views taken across a body lumen and treatment device to show additional aspects of the eccentric treatment methods and devices.

FIGS. 39A and 39B illustrate an eccentric treatment device and method in a gelatin artery model.

FIG. 40 is a perspective view of an exemplary catheter assembly.

DETAILED DESCRIPTION OF THE INVENTION

Non-limiting embodiments of the present invention provide devices, systems, and methods to remodel a partially occluded artery in order to open the artery lumen and increase blood flow. Remodeling may involve the application of electrosurgical energy, typically in the form of RF and/or microwave electrical potentials to energy delivery surfaces such as electrodes, antennas, and the like. This energy will often be controlled so as to limit a temperature of target and/or collateral tissues, for example, limiting the heating of a fibrous cap of a vulnerable plaque or the intimal layer of an artery structure to a maximum structure in a range from about 50 to about 60° Celsius, by limiting the maximum temperature of an outer layer or adventitia of the blood vessel to no more than about 63° Celsius, limiting heating of a lipid-rich pool of a vulnerable plaque sufficiently to induce melting of the lipid pool while inhibiting heating of other tissues (such as an intimal layer or fibrous cap) to less than a temperature in a range from about 50 to about 60° Celsius so as to inhibit an immune response that might otherwise lead to restenosis, or the like. Relatively mild heating energies may be sufficient to denature and shrink atherosclerotic material during treatment, immediately after treatment, and/or more than one hour, more than one day, more than one week, or even more than one month after the treatment through a healing response of the tissue to the treatment so as to provide a bigger vessel lumen and improved blood flow.

In some embodiments, remodeling of the atherosclerotic plaque may comprise the use of higher energies to ablate and remove occlusive material from within body lumens, and particularly to remove atherosclerotic material from a blood vessel in order to improve blood flow. Ablation debris may be generated by such ablation, and the ablation debris may be thrombolitic or non-thrombolitic. Where thrombolitic debris is generated by ablation, that debris may be restrained, captured, and/or evacuated from the treatment site. Non-thrombolitic debris produced by ablation may not have to be restrained and/or evacuated from the vessel. The techniques of the invention will often provide electrosurgical capabilities, sensing or imaging suitable for measuring atheroma and/or vascular walls, and/or an emboli inhibitor. As atherosclerosis may be eccentric relative to an axis of the blood vessel over 50% of the time, possibly in as much as (or even more than) 75% of cases, the devices and methods of the present invention will often be particularly well suited for directing treatment eccentrically, often in response to circumferential atherosclerotic material detecting or imaging. While the methods and devices described herein allow such eccentric treatments, the devices can also be used for treatment of radially symmetric atherosclerosis by selectively directing energy in a radially symmetric pattern about an axis of the catheter or the like.

Hence, remodeling of atherosclerotic materials may comprise ablation, removal, shrinkage, melting, and the like of atherosclerotic and other plaques. Optionally, atherosclerotic material within the layers of an artery may be denatured so as to improve blood flow, so that debris will not necessarily be generated. Similarly, atherosclerotic materials within the arterial layers may be melted and/or treatment may involve a shrinking of atherosclerotic materials within the artery layers, again without necessarily generating treatment debris. The invention may also provide particular advantages for treatment of vulnerable plaques or blood vessels in which vulnerable plaque is a concern. Such vulnerable plaques may comprise eccentric lesions, and the present invention may be particularly well suited for identifying an orientation (as well as axial location) of the vulnerable plaque structure. The invention will also find applications for targeting the cap structure for mild heating (to induce thickening of the cap and make the plaque less vulnerable to rupture) and/or heating of the lipid-rich pool of the vulnerable plaque (so as to remodel, denature, melt, shrink, and/or redistribute the lipid-rich pool.

While the present invention may be used in combination with stenting and/or balloon dilation, the present invention is particularly well suited for increasing the open diameter of blood vessels in which stenting and balloon angioplasty are not a viable option. Potential applications include treatment of diffuse disease, in which atherosclerosis is spread along a significant length of an artery rather than being localized in one area. The invention may also provide advantages in treatment of vulnerable plaque or blood vessels in which vulnerable plaque is a concern, both by potentially identifying and avoiding treatment of the vulnerable plaque with selected eccentric and/or axial treatments separated from the vulnerable plaque, and by intentionally ablating and aspirating the cap and lipid-rich pool of the vulnerable plaque within a controlled environmental zone or region within the blood vessel lumen. The invention may also find advantageous use for treatment of tortuous, sharply-curved vessels, as no stent need be advanced into or expanded within the sharp bends of many blood vessel. Still further advantageous applications include treatment along bifurcations (where side branch blockage may be an issue) and in the peripheral extremities such as the legs, feet, and arms (where crushing and/or stent fracture failure may be problematic).

Diffuse disease and vulnerable plaque are illustrated in FIGS. 1A and 1B, respectively. FIG. 1C illustrates vascular tortuosity. FIG. 1D illustrates atherosclerotic material at a bifurcation, while FIG. 1E illustrates a lesion which can result from atherosclerotic disease of the extremities.

FIG. 1F illustrates a stent structural member fracture which may result from corrosion and/or fatigue. Stents may, for example, be designed for a ten-year implant life. As the population of stent recipients lives longer, it becomes increasingly likely that at least some of these stents will remain implanted for times longer than their designed life. As with any metal in a corrosive body environment, material degradation may occur. As the metal weakens from corrosion, the stent may fracture. As metal stents corrode, they may also generate foreign body reaction and byproducts which may irritate adjoining body tissue. Such scar tissue may, for example, result in eventual reclosure or restenosis of the artery.

Arterial dissection and restenosis may be understood with reference to FIGS. 1G through 1I. The artery comprises three layers, an endothelial layer, a medial layer, and an adventitial layer. During angioplasty, the inside layer may delaminate or detach partially from the wall so as to form a dissection as illustrated in FIG. 1G. Such dissections divert and may obstruct blood flow. As can be understood by comparing FIGS. 1H and 1I, angioplasty is a relatively aggressive procedure which may injure the tissue of the blood vessel. In response to this injury, in response to the presence of a stent, and/or in the continuing progression of the original atherosclerotic disease, the opened artery may restenose or subsequently decrease in diameter as illustrated in FIG. 1I. While drug eluting stents have been shown to reduce restenosis, the efficacy of these new structures several years after implantation has not be fully studied, and such drug eluting stents are not applicable in many blood vessels.

In general, the present invention provides a catheter which is relatively quick and easy to use by the physician. The catheter system of the present invention may allow arteries to be opened to at least 85% of their nominal or native artery diameter. In some embodiments, arteries may be opened to about 85%, and/or acute openings may be less than 85%. Rapid occlusive material removal may be effected using sufficient power to heat tissues locally to over about 100° C. so as to vaporize tissues, or more gentle remodeling may be employed.

The desired opening diameters may be achieved immediately after treatment by the catheter system in some embodiments. Alternatively, a milder ablation may be implemented, for example, providing to no more than a 50% native diameter when treatment is complete, but may still provide as much as 80 or even 85% or more native vessel open diameters after a subsequent healing process is complete, due to resorption of injured luminal tissues in a manner analogous to left ventricular ablation for arrhythmia and transurethral prostate (TURP) treatments. Such embodiments may heat at least some occlusive tissue to a temperature in a range from about 55° C. to about 80° C. In some embodiments, occlusive tissues may be heated to a maximum temperature in a range between about 93 and 95° C. In other embodiments described herein, heating may be controlled so as to provide tissue temperatures in a range between about 50 and 60° C., with some embodiments benefiting from maximum tissue temperatures of about 63° C. Still further treatments may benefit from treatment temperatures of about 90° C. Advantageously, the catheter systems and methods of the invention may be used without balloon angioplasty, thereby avoiding dissections and potentially limiting restenosis.

An exemplary catheter system 10 is schematically illustrated in FIGS. 2 and 2A. A remodeling and/or ablation catheter 12 includes a catheter body 14 having a proximal end 16 and a distal end 18. Catheter body 14 is flexible and defines a catheter axis 20, and includes an aspiration lumen 22 and an irrigation lumen 24 (see FIG. 3). Still further lumens may be provided for a guidewire, imaging system, or the like as described below. Lumen 22 may be used for sensing and/or imaging of atheroma as well as aspiration.

Catheter 12 includes a radially expandable structure 26 adjacent distal end 18 and a housing 28 adjacent proximal end 16. A distal tip 30 may include an integral tip valve to seal aspiration lumen 22 and allow passage of guidewires, imaging and/or restenosis inhibiting catheters, and the like.

Proximal housing 28 includes a first connector 32 in fluid communication with aspiration lumen 22. Aspiration lumen 22 may have an aspiration port within expandable structure 26 so as to allow aspiration or aspiration of debris and gasses from within the expandable structure. Aspiration lumen 22 may also be used as an access lumen for guidewires, intravascular imaging catheters, and/or distally advancing intravascular radiation treatment catheters or restenosis inhibiting drugs. Hence, connector 32 may selectively accommodate an imaging catheter 34 having an atherosclerotic material detector 36 advancable within catheter body 14 adjacent to and/or beyond distal end 18, the detector often comprising an intravascular ultrasound transducer, an optical coherent tomography sensor, an MRI antenna, or the like. An imaging connector 38 of imaging catheter 34 transmits imaging signals allowing circumferential measurement of atherosclerotic thicknesses about axis 20 to a display 39.

Connector 32 also accommodates a restenosis inhibiting treatment catheter 40, the treatment catheter here comprising an intravascular radiation catheter. Such a radiation catheter may include a radiation source 42 which can again be advanced distally within catheter body 14 to or beyond expandable structure 26.

A second connector 44 of proximal housing 28 is in fluid communication with irrigation lumen 24 (see FIG. 3). Second connector 44 may be coupled to an irrigation fluid source for introducing conductive or non-conductive liquids, gases, or the like, ideally for introducing gas or heparinized saline. Both first and second connectors 32, 44 may optionally comprise a standard connector such as a Luer-Loc™ connector. In FIG. 2A connector 44 is schematically shown coupled to an aspiration vacuum source/infusion fluid source 45.

Referring now to FIGS. 2, 2A, and 3, proximal housing 28 also accommodates an electrical connector 46. Connector 46 includes a plurality of electrical connections, each electrically coupled to an electrode 50 via a dedicated conductor 52. This allows a subset of electrodes 50 to be easily energized, the electrodes often being energized with bipolar or monopolar RF energy. Hence, electrical connector 46 will often be coupled to an RF generator via a controller 47, with the controller allowing energy to be selectively directed to an eccentric portion of an engaged luminal wall. When monopolar RF energy is employed, patient ground may (for example) be provided by an external electrode or an electrode on catheter body 14. A processor 49 may manipulate signals from imaging catheter 34 to generate an image on display 39, may coordinate aspiration, irrigation, and/or treatment, and may automatically register the treatment with the image.

Expandable structure 26 is illustrated in more detail in FIG. 3. Expandable structure 26 may expand resiliently when released from within a restraining sheath, or may expand by pulling tip 30 toward distal end 18 (see FIG. 2), optionally using a pullwire, an inner catheter body 58, or the like. Expandable structure 26 here comprises a perforate structure or basket having a series of structural struts or elements 54 with opening or perforations 56 therebetween. Perforations 56 may be formed, for example, by cutting elongate slits in a flexible tube material, or the basket may be formed by braiding elongate wires or ribbons or the like.

Expandable structure 26 generally includes a proximal portion 60, a distal portion 62, and an intermediate portion 64 therebetween. Each electrode 50 is mounted on an associated basket element 54 along intermediate portion 64, with an associated conductor 52 extending proximally from the electrode. Electrodes 50 are distributed circumferentially about axis 20 in an array, adjacent electrodes preferably being axially offset, ideally being staggered or alternating between proximal and distal axial locations. This allows bipolar energy to be directed between adjacent circumferential (axially offset) electrodes between adjacent distal electrodes, between adjacent proximal electrodes, and the like.

In the exemplary embodiment, proximal and distal barriers 66, 68 expand radially with proximal and distal portions 60, 62 of expandable structure 26. Barriers 66, 68 inhibit any ablation debris and gases generated adjacent electrodes 50 from traveling within the body lumen beyond catheter 12. Barriers 66, 68 also allow an at least partially isolated ablation environment to be established within the body lumen, for example, by replacing blood within a blood vessel with a more advantageous fluid environment for limiting charring of the electrodes and the like. Alternative barriers may be provided instead of (or in combination with) barriers 66, 68, including one or more balloons axially offset from expandable member 26, elastic lips as shown in FIG. 11-13, or the like. In other embodiments remodeling may be effected without generating significant thermolytic ablation debris and/or a desired treatment environment may be provided with localized irrigation and/or aspiration flows so that some systems may forego the use of barriers.

Referring now to FIGS. 4 and 6A, alternative embodiments may use different expandable structures in the form of different baskets. In FIG. 4, a braided basket 70 includes electrodes 50 mounted on braided structures 72. While metallic braided structures may be used in some embodiments with attention to electrical isolation of the electrodes, shorting of crossing metallic braided structures may be problematic. Hence, braided members 72 may comprise a high-temperature polymer or non-conductive material such as polyimide. An elongate electrode basket 76 may include electrodes 50 formed, for example, by selectively exposing a metallic surface along a central portion of basket member 78, while the remainder of the basket element is electrically isolated using a high-temperature polymer or the like so that the basket struts may be used as a conductor for energizing the electrode. Radial expansion of basket 76 is also illustrated by movement 71 of inner catheter body 58 relative to body 14. Expansion may also be effected by withdrawing a sleeve from over the basket, a pull wire, or the like. An intravascular ultrasound image sensor 36 of imaging catheter 34 is illustrated in FIG. 5 distal of expandable structures 76, with a proximal portion of the imaging catheter removed for clarity. Still further alternative expandable structures may be employed, including systems in which an array of electrodes is mounted circumferentially about a balloon, which may reduce blood contamination in the ablation area. Alternatively, a controlled ablation environment may be maintained with barriers proximally and/or distally of the expandable member by axially offset balloons, with an optional aspiration port again being disposed between such proximal and distal barriers.

An exemplary expandable structure 26 is formed by cutting slots in a superelastic alloy tube such as a nickel titanium alloy or Nitinol™ tube. As can be understood with reference to FIG. 6B, expandable structures 54 may have circumferential widths 80 which are enhanced adjacent an electrode and/or electrode mounting location 82. As can be seen in FIG. 6A, the localized enhancement of the width 80 adjacent electrode mounting pads 82 may be axially offset, as described above. The slots forming expandable members 54, and hence the expandable members themselves may, for example, be 0.8 inches in length, with the expandable members having a circumferential width of about 0.25 inches.

Referring now to FIGS. 7A and 7B, side and end views of an expandable barrier in the form of a collapsible cone can be seen. Barrier 66 here comprises a braided Nitinol™ wire 84 coated in silicone, for example, by dipping a braid of a superelastic alloy such as a Nitinol™ braid in liquid silicone and allowing it to harden. Such cones may then be mounted over the proximal and distal portions of the expandable structure. As noted above, a variety of alternative barrier membranes may be employed. FIG. 7C illustrates a basket 75 with an integral barrier 77 coated directly on the basket. Barrier 77 comprises a polyurethane, which may be quite tear resistant. Alternative barrier membranes may comprise other materials such as PTFE or the like.

Referring now to FIGS. 8 and 9, exemplary electrodes 50 supported by polyimide alloy expandable members 54 may be coated with a high-temperature polymer. Conductors 52 extend proximally from electrodes 50 as described above. High contrast radiopaque markers such as gold, platinum, platinum/iridium alloy, and the like may be attached to or near these struts. The markers could also be used as the electrodes.

The use of catheter system 10 for remodeling and/or removal of eccentric atheroma from within a blood vessel can be understood with reference to FIGS. 10A through 10E. As seen in FIG. 10A, accessing of a treatment site will often involve advancing a guidewire GW within a blood vessel V at, and more often distally beyond a target region of atherosclerotic material AM. A wide variety of guidewires may be used. For accessing a vessel having a total occlusion, guidewire GW may comprise any commercially available guidewire suitable for crossing such a total occlusion, including the Safe-Cross™ RF system guidewire having forward-looking optical coherence reflectrometry and RF ablation. Where atherosclerotic material AM does not result in total occlusion of the lumen, such capabilities need not be provided in guidewire GW, although other advantageous features may be provided. For example, guidewire GW may include a distal balloon to hold the guidewire in place and further inhibit movement of ablation debris and the like. Guidewire GW may be positioned under fluoroscopic (or other) imaging.

Catheter 12 is advanced distally over guidewire GW and positioned adjacent to atherosclerotic material AM, often toward a distal portion of the occlusion as can be understood with reference to FIGS. 10A and 10B. Expandable structure 26 expands radially within the lumen of the blood vessel so that electrodes 50 radially engage atherosclerotic material AM. Expandable structure 26 may be expanded by, for example, pulling a pullwire extending through catheter body 14 to the coupled (directly or indirectly) to distal portion 62 of expandable body 26 (see FIG. 3). Alternatively, an inner catheter body 58 may be moved proximally relative to outer catheter body 14, with the inner catheter again being coupled to the distal portion of the expandable body. Still further alternatives are possible, including withdrawing a sheath from around the expandable body and allowing the expandable body to flex radially outwardly. In at least some embodiments, whether actuated from the proximal end of catheter 12 or simply by releasing the expandable body, the structural members defining the expandable body may comprise elastic or superelastic materials treated to expand radially outwardly, such as by heat-setting a superelastic Nitinol™ metal, polyimide, or the like. In some embodiments, guidewire GW may be removed after the ablation catheter is positioned and/or the basket is expanded. As atherosclerotic material AM is distributed eccentrically about catheter 12, some of electrodes 50 directly engage a luminal wall W, as can be understood with reference to FIGS. 10B and 10C.

Imaging catheter 34 is positioned within a lumen of catheter 12 so that detector 42 extends to adjacent atherosclerotic material AM. The imaging catheter operates within and/or through catheter 12 so as to measure a thickness of atherosclerotic material concentrically about catheter 12 as illustrated in FIG. 10C with measurements often being taken at a plurality of axial locations so as to measure axial variation of the atherosclerotic material AM within the blood vessel, such measurements often progressing proximally. In many cases, atherosclerotic material AM will be distributed eccentrically within the vessel wall as shown in FIG. 10C. It should be noted that no portion of the vessel wall need be completely uncovered by atherosclerotic material for the measurement distribution to indicate that the obstruction is eccentric, as a relatively thin layer of atheroma along one portion or side of the blood vessel may be much different in thickness than a very thick layer of atherosclerotic material on an opposite side of the blood vessel V. In some methods, remodeling and/or ablation of all atheroma along one side may result in electrode/vessel wall engagement only after treatment begins.

In some cases, imaging catheter 34 may allow identification and/or characterization of atherosclerotic materials, plaques, tissues, lesions, and the like from within a blood vessel. For example, imaging catheter 34 may determine an axial and/or circumferential localization of a target plaque for treatment. Where treatments are intended for atherosclerotic plaques so as to enhance blood flow through the lumen, the treatment may be tailored to provide short term and/or long term increases in lumen diameter and blood flow. Where catheter 34 identifies a circumferentially and/or axially localized vulnerable plaque, that vulnerable plaque may be targeted for a suitable treatment to inhibit deleterious release of thrombolitic materials, often by thickening a fibrous cap of the vulnerable plaque, making the plaque less vulnerable to rupture, decreasing a size or danger of release from a lipid-rich pool of the vulnerable plaque, or the like. Hence, catheter 34 may be used to provide information similar to that available through histology so as to indicate a composition of an atheroma (by identifying and location, for example, a fibrous cap, smooth muscle cells, a lipid pool, calcifications, and the like.) Intravascular ultrasound catheters may now be capable of such atheroma characterizations, and these characterizations may also be provided by optical coherence tomography intravascular catheters, intravascular MRI antennas, and other catheter-based imaging systems, or by non-invasive imaging modalities such as MRI systems, and the like.

Suitable imaging catheters for use in the present catheter system are commercially available from a wide variety of manufacturers. Suitable technology and/or catheters may, for example, be commercially available from SciMed Life Systems and Jomed-Volcano Therapeutics (providers of intravascular ultrasound catheters), Light Lab™ Imaging (developing and commercializing optical coherence tomography catheters for intravascular imaging), Medtronic CardioRhythm, and the like. Still further alternative technologies may be used, including ultra fast magnetic resonance imaging (MRI), electrical impedance atheroma depth measurements, optical coherence reflectrometry, and the like.

The systems, devices, and methods described herein may optionally make use of imaging techniques and/or atherosclerotic material detector devices which are at least in part (optionally being entirely) disposed outside of the body lumen, optionally being disposed outside of the patient body. Non-invasive imaging modalities which may be employed include X-ray or fluoroscopy systems, MRI systems, external ultrasound transducers, and the like. Optionally, external and/or intravascular atherosclerotic material detectors may also be used to provide temperature information. For example, a system having an MRI antenna may detect tissue temperatures such that a graphical indication of treatment penetration may be presented on the system display. Tissue temperature information may also be available from ultrasound and/or optical coherence tomography systems, and the temperature information may be used as feedback for directing ongoing treatments, for selecting tissues for treatment (for example, by identifying a hot or vulnerable plaque), and the like.

As with positioning of guidewire GW and advancement of catheter 12, positioning of sensor 30 of imaging catheter 34 may be facilitated by fluoroscopic or other imaging modalities. Location of sensor 36 relative to expandable structure 26 may be facilitated by radiopaque markers of catheter 34 adjacent sensor 36, and by the radiopaque structure (or corresponding radiopaque markers placed on or near) expandable structure 26, and/or by the use of radiopaque electrodes.

By expanding expandable structure 26 within blood vessel V, optional proximal and distal barriers 66, 68 (see FIG. 3) may form an at least partially, and preferably a substantially isolated environment within the blood vessel. That environment may be adapted to improve subsequent remodeling and/or ablation by aspirating blood from a port of aspiration lumen 22 disposed between proximal and distal barriers 66, 68, and by irrigating the isolated environment with a desired fluid, as described above. When provided, aspiration and/or irrigation may be performed, optionally simultaneously, so as to generate a flow within the controlled environment for removal of any vaporization gases, ablation debris, and the like.

Referring now to FIGS. 10C and 10D, circumferential imaging often indicates that remodeling and/or ablation should be targeted to an eccentric portion or region R of the vessel wall W. To aid in registering the electrodes with the circumferential atheroma distribution, one strut of expandable structure 26 has an identifiable image, allowing the strut to serve as a rotational alignment key. Registering the electrodes may be achieved using intravascular imaging such as intravascular ultrasound (IVUS), optical coherence tomography (“OCT”), intravascular MRI, and/or the like, optionally using external imaging such as fluoroscopy, magnetic resonance imaging (“MRI”), or the like. Electronic registration may also be used. In response to this information, RF energy is directed to electrodes within region R. These actively energized electrodes define a subset of the overall array of electrodes, and selection of this subset of electrodes may be implemented using a controller as described hereinbelow.

The mechanisms of ablating atherosclerotic material within a blood vessel have been well described, including by Slager et al. in an article entitled, “Vaporization of Atherosclerotic Plaque by Spark Erosion” in J. of Amer. Cardiol. (June, 1985), on pp. 1382-6; and by Stephen M. Fry in “Thermal and Disruptive Angioplasty: a Physician's Guide;” Strategic Business Development, Inc., (1990) the full disclosures of which are incorporated herein by reference. Suitable vaporization methods and devices for adaptation and/or use in the present system may also be described in U.S. Pat. Nos. 5,098,431; 5,749,914; 5,454,809; 4,682,596; and 6,582,423, among other references. The full disclosure of each of these references is incorporated herein by reference.

As illustrated in FIG. 10, energizing of selected electrodes 50 may result in vaporization of atherosclerotic material AM, so that the atherosclerotic material is removed from the blood vessel with an aspiration flow F through a lumen of catheter 12. A concurrent irrigation flow helps maintain the environment between the proximal and distal barriers of the catheter, and these two flows allow gases G and ablation debris to be entrained while inhibiting release of such emboli within blood vessel V. The fluid may also act as a cooling fluid to limit heating and collateral damage to other tissues, the circulating fluid often being at least less than body temperature, optionally being at or below room temperature.

Referring now to FIG. 10E, as described above, it may not be necessary to completely remove all atheroma or atherosclerotic material from within the blood vessel. Providing an open lumen having an effective diameter of at least 80 or 85% of a nominal native lumen diameter may be sufficient. Remodeling treatments may provide acute effective open diameters in a range from about 30% to about 50%. In some embodiments, injury caused to the atherosclerotic material with the energized electrodes or other energy directing surfaces may result in subsequent resorption of the injured tissue lesions so as to provide further opening of the vessel after termination of treatment as part of the healing process.

To promote long term efficacy and inhibit restenosis of a treated region of blood vessel V, a restenosis inhibiting catheter 40 may be advanced through a lumen of catheter 12, so that a radiation source 42 irradiates the treated region of the blood vessel. Suitable intravascular radiation catheters are commercially available from Novoste™, Guidant, Johnson & Johnson, and the like. Restenosis inhibiting drugs similar to those now being employed on drug eluting stents may also be advanced through a lumen of catheter 12, optionally while the proximal and distal barriers again help to maintain a controlled environmental zone within the blood vessel, so that systemic drug delivery might be limited or avoided. In addition to known restenosis inhibiting drugs used on drug eluting stents, drugs which cause vasodilation might be employed. Known restenosis inhibiting drugs such as Rapamycin™ may also be used.

In some embodiments, expandable structure 26 may remain expanded against the vessel wall W and/or atherosclerotic material AM while catheter 12 moves within the blood vessel, the catheter often being drawn proximally during or between ablation treatments. Analogous movement of a radially expanded perforate basket is employed, for example, when measuring temperatures of blood vessels so as to detect vulnerable plaque in systems now being developed and/or commercialized by Volcano Therapeutics. Alternatively, the basket may be repeatedly contracted, axial movement of the catheter 12 employed to reposition the basket, with subsequent expansion of the basket at each of a plurality of treatment locations along atherosclerotic material AM. Repeated intravascular imaging or other atherosclerotic material thickness measurements circumferentially about catheter 12 may be employed, with the remodeling and/or ablation often being halted temporarily so as to allow an image to be acquired intermittently during an ablation procedure. A final image may be taken to verify remodeling and/or ablation has been successful.

Referring now to FIGS. 11 through 21, a variety of alternative catheter structures are schematically illustrated, with many of these structures providing a microenvironment or controlled environmental zone within the blood vessel which has been enhanced for remodeling and/or ablation. A variety of emboli inhibiting barriers are also described and/or illustrated, including silastic balloons, flexible lips, or expandable cones which may be axially offset from the ablation electrodes. For example, referring to FIGS. 11 and 12, a system similar to that illustrated in FIG. 2 may employ a remodeling and/or ablation sleeve 102 having a proximal hub 104 and receiving an imaging catheter and a guidewire GW in an axial lumen of the sheath. A microenvironment is provided by a microchamber lip 106, which may comprise silicon or the like. Bipolar electrodes 50 may (though need not necessarily) generate gas and/or other ablation debris, which the silicon lip may help to contain. A vacuum port 108 of hub 104 is in fluid communication with a vacuum port 110, while a saline fluid infusion port 112 together with a saline injection passage 114 may be used to control and/or modify the microenvironment for remodeling and/or ablation. As illustrated in FIG. 13, alternate microchambers may be effected using silicon-like lips 116 fully encircling the catheter sheath 102, dual balloons, or the like. As illustrated in FIG. 14, such structures may be combined with a basket 118 supporting RF electrodes so as to provide electrode contact within a microchamber. The basket may optionally comprise a Nitinol™ shaped memory alloy.

Referring now to FIG. 15, more generally, remodeling/ablation sleeve 102 may support electrode 50 for radiofrequency energy, and may provide one or more lumens for coaxial and/or biaxial insertion of an imaging catheter 34 (such as an IVUS catheter) and/or guidewire GW. Imaging catheter 34 may have a transducer in the form of an array 120.

Referring now to FIG. 16, a remodeling/ablation sleeve 102 similar to that shown in FIGS. 11 and 12 has (here in cross section) has an electrode wire lumen 122, a saline injection lumen 124, and the opening of the vacuum port 110 to the working lumen of sheath 102 in which the imaging or IVUS catheter 34 and guidewire GW are disposed. A silicon lip or valve 126 allows a vacuum to be transferred to the microenvironment.

Still further alternative arrangements are illustrated in FIGS. 17 and 17A. In the embodiment of FIG. 17, an inner electrode 128 is used in a bipolar system along with outer electrodes 50, which contact the tissue for treatment. FIG. 17A schematically illustrates use of a balloon catheter 130 having a balloon 132 (such as a latex balloon). On the surface of the latex balloon electrodes 50 are mounted for use in selected pairs. Hence, a balloon (rather than a basket structure) may be used as a radially expandable structure for carrying the electrodes or other energy delivery surfaces.

FIG. 18 schematically illustrates an expandable basket 134 being contracted from a large configuration to a small configuration. The basket may optionally be used as a cutting basket by providing appropriate edges, and/or may capture emboli within. FIG. 19 illustrates a remodeling/ablation sleeve 102 in which imaging catheter 34 travels axially back and forth to image, and in which a silastic balloon 135 is disposed distal of the treatment debris for emboli capture. FIG. 20 illustrates an alternate electrode delivery balloon 138 similar to balloon 132 of FIG. 17A, and illustrates electrodes 50 having flexible lumen extensions extending proximally therefrom. FIG. 21 schematically illustrates an RF electrode within a microchamber provided by proximal and distal barriers 140, 142 of sheath 102, in which a position of electrode 50 is actuated in the microchamber.

Referring now to FIGS. 22 and 23, alternative controllers 92a, 92b selectively energize electrodes of catheter 12 with RF power supplied from an RF generator 94. A wide range of RF energy types may be employed, including burst of 500 Khz, different types of waveforms, and the like. In controller 92a, a simple dial 96 is turned to point to a desired electrode pair to be energized. A “key” electrode may be registered with the intravascular imaging system, either electronically or by providing an electrode, electrode support member, or attached marker which presents a distinct image on the intravascular imaging display. This simplifies selection of one or more eccentric electrode pair along atheroma. Advantageously, catheter 12 need not be rotated into a proper orientation to accurately remodel and/or ablate the desired eccentric atherosclerotic material. Controller 92b includes similar capabilities, but allows the operator to select multiple electrodes for driving bipolar RF energy therebetween, providing greater flexibility in allowing multiple electrodes to be simultaneously energized. FIGS. 23 and 24 illustrate monopoly control arrangements similar to those of FIGS. 21 and 22, respectively. Patient grounding may be effected by a patient grounding plate, a ring electrode 2 to 5 cm proximal to basket 26, or the like. Once again, no catheter rotation is required to orient an active side of the catheter adjacent to the targeted atheroma since various eccentric ablation orientations can be selected through the electrode selection controller.

FIGS. 26 and 27 schematically illustrate alternative fluid flow arrangements for use in the catheters and methods described herein. In the embodiment of FIG. 26, a tubular body 150 extending proximally from expandable body 26 includes one or more irrigation ports 152, the irrigation ports here being disposed proximally of the expandable body. An aspiration port 154 contains a tubular body defining a guidewire and/or imaging catheter lumen 156. Irrigation fluid may flow distally, which may also be the direction of blood flow in the body lumen. Irrigation fluid may be aspirated through the aspiration port. In the embodiment of FIG. 27, lumen 154 is used for aspiration and for a guidewire and/or imaging catheter.

An alternative controller is illustrated in FIGS. 28A-D. This controller allows an operator to choose, for each electrode, whether to keep that electrode inactive, electrically couple that electrode to a first pole (sometimes referred to as pole A) of an energy source (such as an RF generator or the like), or to electrically couple that electrode to a second pole or pole B of the energy source. This controller allows a wide range of energized electrode configurations, including pseudo-monopolar modes where all electrodes except one are connected to one pole of the energy source (pole A) and one electrode is connected to the other pole (pole B). As can be understood with reference to FIG. 28A, controller 160 allows testing of many electrode configurations for RF remodeling and/or ablation, particularly those involving two or more electrodes. A switch panel 162 is shown in more detail in FIG. 28B. Each electrode (in this embodiment, up to eight electrodes) is electrically coupled to a 3-way switch numbered from 1 to 8, a switch disposed in the middle position indicates the electrode is not coupled to either pole, while a switch pushed toward the plus sign indicates the associated electrode is coupled to a red RF connector with the controller. Similarly, a switch pushed toward the minus sign indicates the associated electrode is electrically coupled to a black RF connector of the control box.

As can be understood with reference to 28C, electrodes associates with switches 3-8 are not coupled to either pole, electrode 1 is connected to the red RF connector, and electrode 2 is connected to the black RF connector. Activation of the RF generator will circulate bipolar RF energy between electrodes 1 and 2. In FIG. 28D, electrodes 5-8 are not energized, while electrodes 1 and 3 are coupled to the red RF connector. Electrodes 2 and 4 are connected to the black RF connector, so that activation of the RF generator will circulate bipolar RF energy between electrodes 1 and 3 and between electrodes 2 and 4.

An exemplary self-expandable basket is illustrated in FIGS. 29A-29H. As can be understood from these drawings, electrodes may be fabricated as part of the struts 172 from which the basket is formed, for example, using a radially outwardly oriented surface of a localized widening 174 of each strut disposed in axially central portion of the strut, as can be seen in FIGS. 29B and 29E. Each arm may be formed from one piece of material, optionally comprising a Nitinol™ nickel-titanium shaped memory alloy, with the struts optionally being laser cut from a Nitinol™ tube. The electrode/basket may be, for example, coated with a high temperature polymer such as a polyimide. Electrodes 174 may be formed by inhibiting coating or removing coating from the desired portion of the associated strut 172 (as illustrated in FIG. 29E) so that the electrode surface is exposed for contact with atherosclerotic material. The struts may be separated from each other and structurally supported with an insulated material such as ultraviolet (“UV”) cure or heat shrink sleeve, a polyethylene, Nylon™, or the like to form basket 170.

Each strut 172 may be used to conduct energy between electrode surface 174 and an electrical conductor extending proximally from the strut toward a controller. Proximal pads for connecting such conductors are illustrated in FIG. 29C, while distal structural pads 178 are illustrated in FIG. 29D. Adjacent electrodes 174 may be axially offset or staggered as can be seen in FIG. 29F. Insulating coating along each strut 172 may be inhibited or removed from an inner surface of proximal pads 176 so as to facilitate connecting of an associated conductive wire, such as by spot welding or the like. Alternative insulating materials may also be used, including parylene coatings, while alternative methods for attaching struts 172 to a catheter body may be employed, including adhesive bonding using insulating UV cure, embedding the pad structures in polyethylene, and the like.

Exemplary structures for fixing struts 172 of basket 170 to a catheter body 180 are illustrated in FIG. 29G.

Referring now to FIGS. 29F and 29H, an alternative indicia providing a distinguishable image for rotationally registering selected electrodes 174 of basket 170 to images or other atherosclerotic material measurements can be understood. In this embodiment, an electrode 174i referenced as electrode 1 may have a radiopaque marker 182 disposed on the associated strut 172i. A strut 172ii supporting an associated second electrode 174ii may have two radiopaque markers 182 provide a circumferentially asymmetric count indicator allowing all electrodes to be referenced without ambiguity. The shape of electrodes 50 may vary, for example, electrodes 174 may be wider than other portions of struts 172 as illustrated in FIGS. 29A-G.

As described above, remodeling will often be performed using irrigation and/or aspiration flows. In many embodiments, an irrigation port directs fluid, such as a saline solution, from an irrigation lumen to an interior of the basket. An aspiration port may provide fluid communication between an aspiration lumen and an interior of the basket. One or both of these fluid flows may be driven continuously, or may alternatively pulsate before, during, and/or after treatment. In some embodiments, aspiration and/or irrigation flow may occur acutely or concurrently so as to circulate between the irrigation port and the aspiration port. Optionally, the flow may carry ablation debris to the aspiration port, where the debris may be evacuated through the aspiration lumen. There may be coordination between the irrigation system and the aspiration system such that the irrigation fluid may remain confined in an area closely adjacent the basket so as to inhibit embolization of ablation debris when the basket is expanded within the blood vessel. Such coordination, for example, may inhibit distal movement of ablation debris, and/or may obviate any need for a distal and/or proximal barrier or membrane. In some embodiments, the circulation of fluid between an irrigation port and an aspiration port may create an effectively bloodless environment adjacent the electrodes to facilitate remodeling and/or ablation, imaging of atherosclerotic tissue, and the like.

Referring now to FIGS. 30A and 30B, control of energy directed from the catheter systems and structures of the present invention may optionally make use of thermocouples and other temperature sensing structures. Thermocouples such as K-type thermocouples (+CH/−AL) may be attached to or near one or more struts of an expandable structure to provide temperature measurements. For example, such structures may provide tissue temperature measurements, blood temperature measurements, treatment temperature measurements, and/or the like.

Optionally, a temperature measurement structure may also be used as an RF electrode, for example, by employing one or more of the structures illustrated in FIGS. 30A and 30B. In the embodiment of FIG. 30A, a thermocouple 182 can be coupled to either an RF energy source 184 or a thermometer 186 by a switch 188. A similar embodiment is illustrated in FIG. 30B.

Referring now to FIG. 31, an alternative catheter system 190 includes a plurality of electrodes 50 supported by struts 192. Struts 192 expand radially when extended distally through a sheath 194 so that a circumferential array of the electrodes is collapsible. A ball-shaped tip 196 includes proximally oriented high pressure jets 198, and the ball-shaped tip may be used as one pole with selected electrodes 50 being used as the other pole. Alternatively, bipolar power may be driven between electrodes 50 or the like. Optionally, a proximal barrier 200 such as a screen may be used to inhibit movement and/or capture any debris.

When the RF electrodes are energized, the high pressure jets may also be activated so as to provide a saline flush. A venturi effect may entrain the debris for transport proximally through a catheter lumen for evacuation, typically using an aspiration source coupled to sheath 194. Debris may be trapped in barrier 200 which may comprise a screen, a solid sheet, a net, or the like. In some embodiments, low pressure jets may be used from adjacent ball tip 196 in place of high pressure jets.

Referring now to FIGS. 32A-32D, alternative expandable structures may avoid kinking or flattening of the expandable structure when the expandable structure bends axially, such as when it is expanded along a bend in a body lumen. In the embodiment of FIG. 32C, a coil or helical expandable structure 202 has a small profile configuration 204 and a large profile configuration 206, and may be deployed and/or retracted by twisting a distal end 208 and/or a proximal tubular body 210 relative to each other, by a pull/release mechanism, or the like. Aspiration and/or irrigation may be provided through the proximal tubular member 210 as described above, and the coil structure may include a single loop or a plurality of loops so as to provide one or more circumferential rows of electrodes 50 when in the expanded configuration 206. In the embodiment of FIG. 32D, an inflatable expandable structure 212 includes axial struts and/or rings formed as tubular inflatable balloons so as to allow the expandable structure to expand from the small profile configuration to the shown large-profile configuration.

Still further alternative expandable structures and energy delivery surfaces are schematically illustrate in FIGS. 33-35. In a microwave treatment device 216 illustrated in FIG. 33, each strut of a basket may include a helicoidal microwave antenna, with an inner side of the antenna shielded to avoid emitting energy toward the catheter axis. Alternative microwave antennas may also be employed, including unidirectional antennas which allow depth between an energy delivery surface and a target tissue to be varied by varying a focus of the antenna. Such focused microwave devices may include antennas that are rotatable about the catheter axis, axially moveable, and the like.

In the embodiments of FIGS. 34 and 35, catheter bodies again support a series of struts 218, 220 and also have a plurality of irrigation or flush lumens. The irrigation lumens within the catheter body are in fluid communication with tubular structures extending along the (and in some cases being integrated into the) struts, so that fluid flush ports 222 direct saline or other fluids towards electrodes 50 or microwave antennas 224. Electrosurgical power for the energy delivery surfaces may be transmitted using the strut structure, or wires 226 may extend along the strut to the energy delivery surfaces. In the embodiment of FIG. 35, shield 228 along an inner portion of a microwave antenna 224 can be seen, which may limit microwave energy directed toward an imaging catheter. For embodiments employing microwave antennas as energy delivery devices, only one antenna of the circumferential array may be energized at a time, so as to avoid interference between conductors along the catheter body.

Referring now to FIG. 36, controllers of the catheter systems described herein may allow distribution of differing power levels to differing pairs of electrodes. For example, in response to a circumferential distribution of atherosclerotic material AM such as that illustrated in FIG. 36, a controller may direct 50 watts of energy to a first electrode 230, 30 watts of energy to a pair of second electrodes 232 and only 10 watts of energy to a pair of third electrodes 234. Other electrodes may have no energy directed thereto, as described above. In some embodiments, a differing power directed to the differing electrodes may be provided by controlling the duty cycle, for example, with 50 watts being provided by energizing one or more electrode for 50% of the time, 30 watts being provided by energizing an electrode 30% of the time, and the like.

Referring now to FIGS. 37A-37C, many imaging modalities (including intravascular ultrasound, optical coherence tomography, intravascular MRI, and the like) may be at least in part blocked or degraded by positioning the image detecting structure within a metallic structure such as a basket formed of Nitinol™. Hence, there may be advantages in producing alternative expandable structures such as baskets comprising plastics or a polymer. In light of the heat generated by the electrodes of the systems described herein, it may be advantageous for such polymer basket structures 240 to comprise a high temperature polymer such as a polyimide. Alternative basket structures may comprise HDPE, PET, Nylon™, PEBAX™, and the like. As illustrated in FIG. 37B, proximal ends of the basket struts may be glued to a shaft 242 at a bond 244. An imaging catheter guide 246 may extend through a distal end of the basket structure 248, with the distal end of the basket free to slide axially along the guide. Pullwires 250 may be affixed to the distal end 248, so that pulling of the pullwires radially expands basket 240, with the pullwires running inside the proximal shaft 242. The basket may be retracted back to its small profile configuration by pushing of the pullwires, or the basket may include biasing means urging the basket to the small profile configuration. So as to avoid degradation to imaging performance, polymer tension members similar to fishing line may be used as pullwires. In the exemplary embodiment, the pole wires comprise Nitinol™ which has sufficient compressional rigidity to push the basket to its small profile configuration.

Basket 240 may be formed by cutting struts from a tube of the polymer material, with the distal portion 248 preferably remaining uncut. The proximal ends of the struts may be separated prior to forming bond 244, and ring-shaped RF electrodes may be slid along each arm and glued to the desired configuration along the intermediate portion of the basket.

Exemplary treatment methods are illustrated in FIGS. 38A-38H. In FIG. 38A, the catheter system 260 includes a basket covering sheath 262 over an atherosclerotic material detecting and treating catheter 264 as described above. In this embodiment, outer basket sheath 262 radially restrains the basket 266, which is biased to expand radially when released from the outer sheath, as illustrated in FIG. 38B. In some embodiments, the basket may be expanded after the outer sleeve is retracted, such as by pulling pullwires, rotating one portion of the catheter relative to the other, or the like. Regardless, as the basket expands within the vessel V, electrodes 50 of the basket engage the surrounding vessel wall. An imaging transducer near basket 266 of an imaging catheter disposed in a lumen of the treatment catheter evaluates the vessel V, and the detection/treatment catheter system 264 is pulled proximally along the artery or vessel V.

When the imaging catheter detects atherosclerotic material AM as illustrated in FIG. 38C, an appropriate subset (possibly including only a single electrode 50) is activated to remodel the atherosclerotic material AM, as illustrated in FIG. 38D, and the open vessel lumen size increases moderately during treatment. The catheter is pulled proximally to the next atheroma, which is again detected and treated. A cross section of the limited open lumen prior to treatment is schematically illustrated in FIG. 38F, which also illustrates a saline flush or irrigation lumen 268 of the catheter 264. Treatment energy and the moderate increase in the open lumen diameter of the vessel V are schematically illustrated in the cross section of FIG. 38G. After a healing response gradually increases the open lumen diameter, the longer term open lumen results schematically illustrated in FIG. 38H may then be provided.

Referring now to FIGS. 38A and B, eccentric material removal in a gelatin artery model 270 are presented. Prior to the test, the artery model includes a consistent lumen 272 as seen in FIG. 38A. A test eccentric treatment catheter 274 having an expandable basket supporting a circumferential array of electrodes is introduced into lumen 272, with the expandable basket supporting the electrodes in engagement with the luminal wall. Selected electrodes of test catheter 274 were energized so as to eccentrically treat the gelatin artery model 274, thereby effecting eccentric remodeling of the gelatin model, in this case by removing an eccentric volume 276 from along one side of lumen 272. The orientation and amount of the material removed was controlled by selectively energizing electrodes of test catheter 274.

Referring now to FIG. 40, an exemplary catheter system 280 is illustrated. In this embodiment, catheter body 282 includes only a single lumen, which is large enough to accommodate an imaging catheter therein and also to be used as an irrigation lumen to bring irrigation fluid to irrigation ports 284. The lumen may decrease in diameter distally of irrigation ports 284, with the decreased diameter portion 286 fittingly receiving the imaging catheter within the lumen thereof so as to direct the irrigation fluid radially outward through the plurality of irrigation ports. This embodiment may be particularly useful when remodeling atherosclerotic materials using the methods illustrated in FIGS. 38A-38H, in which mild heating improves vessel size without requiring aspiration.

Catheter body 282 may include a braided shaft in which conductive wires (for example copper wires or beryllium-copper wires) are coated with a high temperature and/or high strength insulation material such as a layer of polyimide or the like. The braided wires may be sandwiched between layers of materials forming the shaft of catheter body 282. The shaft may, for example, comprise a plurality of layers of polyethylene, an inner Teflon™ PTFE layer, an outer nylon layer, and the like.

The wires of shaft 282 may be braided so as to inhibit capacitive losses between wires when electrical currents run through them. Capacitive losses may be decreased when a wire that carries a current from an energy source to an electrode of the catheter system and a wire that carries a current from an electrode back to the energy source are not parallel, but at an angle, ideally being perpendicular. This may be achieved by braiding the wires with appropriate pitch or a number of peaks per inch. The basket structure 170 of catheter system 280 may be included, with the basket structure being described in more detail with reference to FIGS. 29A-29H. Guide 286 may extend through basket 170 and may comprise a material transparent to the imaging catheter, optionally comprising HDPE, PET, or the like.

Still further alternatives are available. For example, another way to employ RF energy to remodel atherosclerotic material may be to energize a plurality of the adjacent electrodes with differing RF signals so as to employ the adjacent electrodes as a phase-array. A phase array can direct or steer an electromagnetic signal in a desired direction using constructive and destructive interferences between signals of adjacent elements of the array. By controlling phases of the adjacent signals, a phase array of electrodes may provide a focused and/or steerable RF signal.

Along with controlling steering and directionality, adjusting phases of adjacent RF electrodes may allow focusing of some or most of the RF energy at a desired depth D inside the atherosclerotic material while inhibiting RF energy delivery between the electrode surfaces and depth D using constructive and destructive interference between the signals. For example, such a system may be employed to preserve the cap of a plaque so as to reduce restenosis. Inhibiting heating of the cap while focusing energy toward an internal portion of the plaque may lower an immune response to heat that could otherwise lead to restenosis. Hence, inhibiting heating of the cap may reduce restenosis.

In general, the present invention may use of highly elastic, expandable structures, particularly of expandable structures formed from structural members separated by perforations so as to define a “basket.” Such structures can conform to an artery diameter before, during, and/or after atherosclerotic material removal. This expandability allows for direct contact of the electrodes against atheroma, although the systems of the present invention may also make use of conductive fluid environments to complete an RF energy path, or conversely, use non-conductive fluid to enhance energy directed through tissue. Multiple electrodes can be distributed circumferentially around an intermediate portion of the expandable structure, and a subset of these electrodes can be activated to allow for eccentric tissue remodeling and/or ablation.

Atheroma may be identified and targeted by intravascular imaging, and these capabilities may be integrated into the remodeling and/or ablation catheter. Preferably, the intravascular imaging capabilities will be deployed in a separate catheter which can be advanced within, and removed from the ablation catheter. In general, this intravascular imaging capability allows the progress of the therapy to be monitored so that wall perforation can be avoided, while ideally reducing occlusion to no more than 15% of the overall native vessel diameter (either upon completion of the treatment or after subsequent tissue healing). The ablation catheter may further allow the use of localized radiation or drug delivery for antirestenosis treatments. The ablation catheter may include a relatively large lumen allowing selective use of an intravascular imaging system, a radiation delivery or other treatment catheter, an aspiration of debris and vaporization gases, with these uses often being employed sequentially. A guidewire may make use of this or a separate lumen, and the guidewire may be removed to allow access for the restenosis and/or imaging catheters.

While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modification, adaptations, and changes may be employed. Hence, the scope of the present invention should be limited solely by the appending claims.

Claims

1. A system for remodeling tissue about a body lumen, the system comprising: (a) an energy source;(b) a catheter coupled to the energy source, the catheter including an expandable device comprising a plurality of electrodes sequentially positioned along a length of the expandable device in a helical pattern, wherein the expandable device is configurable between an expanded condition and an unexpanded condition, wherein when in the unexpanded condition, at least some of the plurality of electrodes are longitudinally and circumferentially offset relative to adjacent electrodes, wherein the expandable device moves from the unexpanded condition to the expanded condition upon activation of a release mechanism, wherein the system is configured to remodel a target tissue while inhibiting damage to collateral tissue; and(c) a controller configured to selectively energize a subset of the plurality of electrodes.
2. The system of claim 1, wherein, when the expandable device is in the expanded condition, the plurality of electrodes are in the helical pattern.
3. The system of claim 2, wherein the plurality of electrodes are positioned along an elongated body.
4. The system of claim 3, wherein the elongated body includes at least one helical loop when the expandable device is in the expanded condition.
5. The system of claim 4, wherein the elongated body includes a plurality of helical loops when the expandable device is in the expanded condition.
6. The system of claim 4, wherein the elongated body is substantially straight when the expandable device is in the unexpanded condition.
7. The system of claim 3, wherein the elongated body includes a nickel and titanium alloy.
8. The system of claim 1, wherein at least some of the electrodes are separated from adjacent electrodes by an insulative material.
9. The system of claim 1, wherein the electrodes comprise bipolar or monopolar electrodes.
10. The system of claim 1, further comprising at least one temperature sensor associated with the expandable device.
11. The system of claim 1, further comprising at least one irrigation lumen associated with the expandable device.
12. The system of claim 1, wherein the expandable device is associated with a catheter proximate a distal end of the catheter.
13. A system for remodeling tissue about a body lumen, the system comprising: (a) an energy source;(b) a catheter coupled to the energy source, the catheter including an expandable device comprising a plurality of electrodes sequentially arranged along the expandable device and longitudinally and circumferentially spaced relative to adjacent electrodes, wherein the plurality of electrodes are arranged along an elongated body, wherein the elongated body is configurable between an unexpanded configuration in which the plurality of electrodes are axially and circumferentially offset from adjacent electrodes and an expanded configuration in which the elongated body is a helical shape, wherein the elongated body moves from the unexpanded configuration to the expanded configuration upon activation of a release mechanism, wherein the system is configured to remodel a target tissue while inhibiting damage to collateral tissue; and(c) a controller configured to selectively energize a subset of the plurality of electrodes.
14. The system of claim 13, wherein the helical shape includes a plurality of helical coils.
15. The system of claim 14, wherein the plurality of helical coils are sequentially arranged along the expandable device.
16. The system of claim 13, wherein the elongated body is a tube including at least one irrigation lumen.
17. The system of claim 13, wherein at least some of the plurality of sequentially spaced electrodes are separated from adjacent electrodes by an insulative material.
18. A system for remodeling tissue about a body lumen, the system comprising: (a) an energy source;(b) a catheter coupled to the energy source, the catheter including an expandable device, comprising an elongated body associated with a distal portion of an elongated catheter, the elongated body including a plurality of electrodes sequentially positioned along the elongated body, wherein the elongated body is moveable between an expanded configuration and an un-expanded configuration, wherein, when in the expanded configuration, the elongated body is helical and includes at least one loop, wherein the elongated body moves from the un-expanded configuration to the expanded configuration upon activation of a release mechanism, and wherein, when in the un-expanded configuration, the elongated body is substantially straight and the plurality of electrodes are circumferentially spaced relative to adjacent electrodes; and(c) a controller configured to selectively energize a subset of the plurality of electrodes.
19. The system of claim 18, wherein, when in the expanded configuration, the elongated body includes a plurality of loops.
20. The system of claim 18, wherein the elongated body is a tube including at least one irrigation lumen.
21. The system of claim 18, wherein the elongated body is at least partially formed from a nickel and titanium alloy.
22. A system for remodeling tissue about a body lumen, the system comprising: (a) an energy source;(b) an expandable device associated with an elongated catheter coupled to the energy source, wherein the expandable device moves from an un-expanded configuration to an expanded configuration upon activation of a release mechanism, wherein the expandable device, when in an expanded configuration, includes at least one helical loop, wherein the helical loop includes a plurality of electrodes sequentially spaced along the helical loop and circumferentially spaced relative to adjacent electrodes, and wherein, when in the un-expanded configuration, at least some of the plurality of electrodes are circumferentially offset relative to adjacent electrodes; and(c) a controller configured to selectively energize a subset of the plurality of electrodes.

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/403,920 filed on Feb. 23, 2012, published as U.S. Patent Application Publication No. 2012/0157987, which is a continuation of U.S. patent application Ser. No. 11/864,779 filed on Sep. 28, 2007 (now U.S. Pat. No. 9,125,666), which is a divisional of U.S. patent application Ser. No. 10/938,138, filed on Sep. 10, 2004 (now U.S. Pat. No. 7,291,146), which claims the benefit under 35 USC 119(e) of U.S. Provisional Patent Application No. 60/502,515 filed on Sep. 12, 2003, the full disclosure of each of which is incorporated herein by reference.

US Referenced Citations (1555)

Number	Name	Date	Kind
164184	Kiddee	Jun 1875	A
1167014	O'Brien	Jan 1916	A
2505358	Gusberg	Apr 1950	A
2701559	Cooper	Feb 1955	A
3108593	Glassman	Oct 1963	A
3108594	Glassman	Oct 1963	A
3540431	Mobin	Nov 1970	A
3952747	Kimmell	Apr 1976	A
3996938	Clark, III	Dec 1976	A
4046150	Schwartz et al.	Sep 1977	A
4290427	Chin	Sep 1981	A
4402686	Medel	Sep 1983	A
4483341	Witteles et al.	Nov 1984	A
4574804	Kurwa	Mar 1986	A
4587975	Salo et al.	May 1986	A
4649936	Ungar et al.	Mar 1987	A
4682596	Bales et al.	Jul 1987	A
4699147	Chilson et al.	Oct 1987	A
4709698	Johnston et al.	Dec 1987	A
4765331	Petruzzi et al.	Aug 1988	A
4770653	Shturman	Sep 1988	A
4784162	Ricks et al.	Nov 1988	A
4785806	Deckelbaum et al.	Nov 1988	A
4790310	Ginsburg et al.	Dec 1988	A
4799479	Spears	Jan 1989	A
4823791	D'Amelio et al.	Apr 1989	A
4830003	Wolff et al.	May 1989	A
4849484	Heard	Jul 1989	A
4862886	Clarke et al.	Sep 1989	A
4887605	Angelsen et al.	Dec 1989	A
4784132	Fox et al.	Mar 1990	B1
4920979	Bullara	May 1990	A
4938766	Jarvik	Jul 1990	A
4955377	Lennox et al.	Sep 1990	A
4976711	Parins et al.	Dec 1990	A
5034010	Kittrell et al.	Jul 1991	A
5052402	Bencini et al.	Oct 1991	A
5053033	Clarke et al.	Oct 1991	A
5071424	Reger et al.	Dec 1991	A
5074871	Groshong et al.	Dec 1991	A
5098429	Sterzer et al.	Mar 1992	A
5098431	Rydell	Mar 1992	A
5102402	Dror et al.	Apr 1992	A
RE33925	Bales et al.	May 1992	E
5109859	Jenkins	May 1992	A
5125928	Parins et al.	Jun 1992	A
5129396	Rosen et al.	Jul 1992	A
5139496	Hed	Aug 1992	A
5143836	Hartman et al.	Sep 1992	A
5156151	Imran	Oct 1992	A
5156610	Reger et al.	Oct 1992	A
5158564	Schnepp-Pesch	Oct 1992	A
5170802	Mehra	Dec 1992	A
5178620	Eggers et al.	Jan 1993	A
5178625	Groshong et al.	Jan 1993	A
5190540	Lee	Mar 1993	A
5191883	Lennox et al.	Mar 1993	A
5211651	Reger et al.	May 1993	A
5234407	Teirstein et al.	Aug 1993	A
5242441	Avitall	Sep 1993	A
5251634	Weinberg et al.	Oct 1993	A
5254098	Ulrich et al.	Oct 1993	A
5255679	Imran	Oct 1993	A
5263493	Avitall	Nov 1993	A
5267954	Nita et al.	Dec 1993	A
5277201	Stern et al.	Jan 1994	A
5282484	Reger et al.	Feb 1994	A
5286254	Shapland et al.	Feb 1994	A
5295484	Marcus	Mar 1994	A
5297564	Love et al.	Mar 1994	A
5300068	Rosar et al.	Apr 1994	A
5301683	Durkan	Apr 1994	A
5304115	Pflueger et al.	Apr 1994	A
5304121	Sahatjian	Apr 1994	A
5304171	Gregory et al.	Apr 1994	A
5304173	Kittrell et al.	Apr 1994	A
5306250	March et al.	Apr 1994	A
5312328	Nita et al.	May 1994	A
5314466	Stern et al.	May 1994	A
5322064	Lundquist	Jun 1994	A
5324255	Passafaro et al.	Jun 1994	A
5326341	Lew et al.	Jul 1994	A
5326342	Pflueger et al.	Jul 1994	A
5330518	Neilson et al.	Jul 1994	A
5333614	Feiring	Aug 1994	A
5342292	Nita et al.	Aug 1994	A
5344395	Whalen et al.	Sep 1994	A
5345936	Pomeranz et al.	Sep 1994	A
5364392	Warner et al.	Nov 1994	A
5365172	Hrovat et al.	Nov 1994	A
5368557	Nita et al.	Nov 1994	A
5368558	Nita et al.	Nov 1994	A
5372138	Crowley et al.	Dec 1994	A
5380274	Nita et al.	Jan 1995	A
5380319	Saito et al.	Jan 1995	A
5382228	Nita et al.	Jan 1995	A
5383874	Jackson et al.	Jan 1995	A
5383917	Desai et al.	Jan 1995	A
5397301	Pflueger et al.	Mar 1995	A
5397339	Desai	Mar 1995	A
5401272	Perkins et al.	Mar 1995	A
5403311	Abele et al.	Apr 1995	A
5405318	Nita et al.	Apr 1995	A
5405346	Grundy et al.	Apr 1995	A
5409000	Imran	Apr 1995	A
5417672	Nita et al.	May 1995	A
5419767	Eggers et al.	May 1995	A
5427118	Nita et al.	Jun 1995	A
5432876	Appeldorn et al.	Jul 1995	A
5441498	Perkins et al.	Aug 1995	A
5447509	Mills et al.	Sep 1995	A
5451207	Yock et al.	Sep 1995	A
5453091	Taylor et al.	Sep 1995	A
5454788	Walker et al.	Oct 1995	A
5454809	Janssen	Oct 1995	A
5455029	Hartman et al.	Oct 1995	A
5456682	Edwards et al.	Oct 1995	A
5457042	Hartman et al.	Oct 1995	A
5471982	Edwards et al.	Dec 1995	A
5474530	Passafaro et al.	Dec 1995	A
5478351	Meade et al.	Dec 1995	A
5496311	Abele et al.	Mar 1996	A
5496312	Klicek et al.	Mar 1996	A
5498261	Strul	Mar 1996	A
5505201	Grill et al.	Apr 1996	A
5505730	Edwards	Apr 1996	A
5507744	Tay et al.	Apr 1996	A
5522873	Jackman et al.	Jun 1996	A
5531520	Grimson et al.	Jul 1996	A
5540656	Pflueger et al.	Jul 1996	A
5540679	Fram et al.	Jul 1996	A
5540681	Strul et al.	Jul 1996	A
5542917	Nita et al.	Aug 1996	A
5545161	Imran	Aug 1996	A
5562100	Kittrell et al.	Oct 1996	A
5571122	Kelly et al.	Nov 1996	A
5571151	Gregory	Nov 1996	A
5573531	Gregory et al.	Nov 1996	A
5573533	Strul	Nov 1996	A
5584831	McKay	Dec 1996	A
5584872	Lafontaine et al.	Dec 1996	A
5588962	Nicholas et al.	Dec 1996	A
5599346	Edwards et al.	Feb 1997	A
5601526	Chapelon et al.	Feb 1997	A
5609606	O'Boyle et al.	Mar 1997	A
5626576	Janssen	May 1997	A
5630837	Crowley	May 1997	A
5637090	McGee et al.	Jun 1997	A
5643255	Organ	Jul 1997	A
5643297	Nordgren et al.	Jul 1997	A
5647847	Lafontaine et al.	Jul 1997	A
5649923	Gregory et al.	Jul 1997	A
5651780	Jackson et al.	Jul 1997	A
5653684	Laptewicz et al.	Aug 1997	A
5662671	Barbut et al.	Sep 1997	A
5665062	Houser	Sep 1997	A
5665098	Kelly et al.	Sep 1997	A
5666964	Meilus	Sep 1997	A
5667490	Keith et al.	Sep 1997	A
5672174	Gough et al.	Sep 1997	A
5676693	Lafontaine	Oct 1997	A
5678296	Fleischhacker et al.	Oct 1997	A
5680860	Imran	Oct 1997	A
5681282	Eggers et al.	Oct 1997	A
RE35656	Feinberg	Nov 1997	E
5688266	Edwards et al.	Nov 1997	A
5693015	Walker et al.	Dec 1997	A
5693029	Leonhardt et al.	Dec 1997	A
5693043	Kittrell et al.	Dec 1997	A
5693082	Warner et al.	Dec 1997	A
5695504	Gifford et al.	Dec 1997	A
5697369	Long, Jr. et al.	Dec 1997	A
5697909	Eggers et al.	Dec 1997	A
5702386	Stern et al.	Dec 1997	A
5702433	Taylor et al.	Dec 1997	A
5706809	Littmann et al.	Jan 1998	A
5713942	Stern et al.	Feb 1998	A
5715819	Svenson et al.	Feb 1998	A
5722401	Pietroski et al.	Mar 1998	A
5735846	Panescu et al.	Apr 1998	A
5741214	Ouchi et al.	Apr 1998	A
5741248	Stern et al.	Apr 1998	A
5741249	Moss et al.	Apr 1998	A
5743903	Stern et al.	Apr 1998	A
5748347	Erickson	May 1998	A
5749914	Janssen	May 1998	A
5755682	Knudson et al.	May 1998	A
5755715	Stern et al.	May 1998	A
5755753	Knowlton et al.	May 1998	A
5769847	Panescu et al.	Jun 1998	A
5769880	Truckai et al.	Jun 1998	A
5775338	Hastings	Jul 1998	A
5776174	Van Tassel	Jul 1998	A
5779698	Clayman et al.	Jul 1998	A
5782760	Schaer	Jul 1998	A
5785702	Murphy et al.	Jul 1998	A
5792105	Lin et al.	Aug 1998	A
5797849	Vesely et al.	Aug 1998	A
5797903	Swanson et al.	Aug 1998	A
5800484	Gough et al.	Sep 1998	A
5800494	Campbell et al.	Sep 1998	A
5807306	Shapland et al.	Sep 1998	A
5810802	Panescu et al.	Sep 1998	A
5810803	Moss et al.	Sep 1998	A
5810810	Tay et al.	Sep 1998	A
5817092	Behl	Oct 1998	A
5817113	Gifford et al.	Oct 1998	A
5817144	Gregory et al.	Oct 1998	A
5823956	Roth et al.	Oct 1998	A
5827203	Nita et al.	Oct 1998	A
5827268	Laufer	Oct 1998	A
5829447	Stevens et al.	Nov 1998	A
5830213	Panescu et al.	Nov 1998	A
5830222	Makower	Nov 1998	A
5832228	Holden et al.	Nov 1998	A
5833593	Liprie	Nov 1998	A
5836874	Swanson et al.	Nov 1998	A
5840076	Swanson et al.	Nov 1998	A
5843016	Lugnani et al.	Dec 1998	A
5846238	Jackson et al.	Dec 1998	A
5846239	Swanson et al.	Dec 1998	A
5846245	McCarthy et al.	Dec 1998	A
5848969	Panescu et al.	Dec 1998	A
5853411	Whayne et al.	Dec 1998	A
5855614	Stevens et al.	Jan 1999	A
5860974	Abele	Jan 1999	A
5865801	Houser	Feb 1999	A
5868735	Lafontaine et al.	Feb 1999	A
5868736	Swanson et al.	Feb 1999	A
5869127	Zhong	Feb 1999	A
5871483	Jackson et al.	Feb 1999	A
5871524	Knowlton et al.	Feb 1999	A
4788975	Shturman et al.	Mar 1999	B1
5875782	Ferrari et al.	Mar 1999	A
5876369	Houser	Mar 1999	A
5876374	Alba et al.	Mar 1999	A
5876397	Edelman et al.	Mar 1999	A
5879348	Owens et al.	Mar 1999	A
5891114	Chien et al.	Apr 1999	A
5891135	Jackson et al.	Apr 1999	A
5891136	McGee et al.	Apr 1999	A
5891138	Tu et al.	Apr 1999	A
5895378	Nita	Apr 1999	A
5897552	Edwards et al.	Apr 1999	A
5902328	Lafontaine et al.	May 1999	A
5904651	Swanson et al.	May 1999	A
5904667	Falwell et al.	May 1999	A
5904697	Gifford et al.	May 1999	A
5904709	Arndt et al.	May 1999	A
5906614	Stern et al.	May 1999	A
5906623	Peterson	May 1999	A
5906636	Casscells et al.	May 1999	A
5916192	Nita et al.	Jun 1999	A
5916227	Keith et al.	Jun 1999	A
5916239	Geddes et al.	Jun 1999	A
5919219	Knowlton et al.	Jul 1999	A
5924424	Stevens et al.	Jul 1999	A
5925038	Panescu et al.	Jul 1999	A
5934284	Plaia et al.	Aug 1999	A
5935063	Nguyen	Aug 1999	A
5938670	Keith et al.	Aug 1999	A
5947977	Slepian et al.	Sep 1999	A
5948011	Knowlton et al.	Sep 1999	A
5951494	Wang et al.	Sep 1999	A
5951539	Nita et al.	Sep 1999	A
5954717	Behl et al.	Sep 1999	A
5957882	Nita et al.	Sep 1999	A
5957941	Ream et al.	Sep 1999	A
5957969	Warner et al.	Sep 1999	A
5961513	Swanson et al.	Oct 1999	A
5964757	Ponzi et al.	Oct 1999	A
5967976	Larsen et al.	Oct 1999	A
5967978	Littmann et al.	Oct 1999	A
5967984	Chu et al.	Oct 1999	A
5971975	Mills et al.	Oct 1999	A
5972026	Laufer et al.	Oct 1999	A
5980563	Tu et al.	Nov 1999	A
5989208	Nita et al.	Nov 1999	A
5989284	Laufer	Nov 1999	A
5993462	Pomeranz et al.	Nov 1999	A
5997497	Nita et al.	Dec 1999	A
5999678	Murphy et al.	Dec 1999	A
6004269	Crowley et al.	Dec 1999	A
6004316	Laufer et al.	Dec 1999	A
6007514	Nita	Dec 1999	A
6010522	Barbut et al.	Jan 2000	A
6013033	Berger et al.	Jan 2000	A
6014590	Whayne et al.	Jan 2000	A
6019757	Scheldrup	Feb 2000	A
6022309	Celliers et al.	Feb 2000	A
6023638	Swanson	Feb 2000	A
6024740	Lesh	Feb 2000	A
6030611	Gorecki et al.	Feb 2000	A
6032675	Rubinsky et al.	Mar 2000	A
6033357	Ciezki et al.	Mar 2000	A
6033397	Laufer et al.	Mar 2000	A
6033398	Farley et al.	Mar 2000	A
6036687	Laufer et al.	Mar 2000	A
6036689	Tu et al.	Mar 2000	A
6041260	Stern et al.	Mar 2000	A
6050994	Sherman et al.	Apr 2000	A
6053873	Govari et al.	Apr 2000	A
6056744	Edwards	May 2000	A
6056746	Goble et al.	May 2000	A
6063085	Tay et al.	May 2000	A
6066096	Smith et al.	May 2000	A
6066139	Ryan et al.	May 2000	A
6068638	Makower	May 2000	A
6068653	Lafontaine	May 2000	A
6071277	Farley et al.	Jun 2000	A
6071278	Panescu et al.	Jun 2000	A
6078839	Carson	Jun 2000	A
6079414	Roth	Jun 2000	A
6080171	Keith et al.	Jun 2000	A
6081749	Ingle et al.	Jun 2000	A
6083159	Driscoll, Jr. et al.	Jul 2000	A
6086581	Reynolds et al.	Jul 2000	A
6091995	Ingle et al.	Jul 2000	A
6093166	Knudson et al.	Jul 2000	A
6096021	Helm et al.	Aug 2000	A
6099526	Whayne et al.	Aug 2000	A
6102908	Tu et al.	Aug 2000	A
6106477	Miesel et al.	Aug 2000	A
6110187	Donlon et al.	Aug 2000	A
6114311	Parmacek et al.	Sep 2000	A
6117101	Diederich et al.	Sep 2000	A
6117128	Gregory	Sep 2000	A
6120476	Fung et al.	Sep 2000	A
6120516	Selmon et al.	Sep 2000	A
6121775	Pearlman	Sep 2000	A
6123679	Lafaut et al.	Sep 2000	A
6123682	Knudson et al.	Sep 2000	A
6123702	Swanson et al.	Sep 2000	A
6123703	Tu et al.	Sep 2000	A
6123718	Tu et al.	Sep 2000	A
6129725	Tu et al.	Oct 2000	A
6135997	Laufer et al.	Oct 2000	A
6142991	Schatzberger et al.	Nov 2000	A
6142993	Whayne et al.	Nov 2000	A
6149647	Tu et al.	Nov 2000	A
6152899	Farley et al.	Nov 2000	A
6152912	Jansen et al.	Nov 2000	A
6156046	Passafaro et al.	Dec 2000	A
6158250	Tibbals et al.	Dec 2000	A
6159187	Park et al.	Dec 2000	A
6159225	Makower	Dec 2000	A
6161048	Sluijter et al.	Dec 2000	A
6162184	Swanson et al.	Dec 2000	A
6165163	Chien et al.	Dec 2000	A
6165172	Farley et al.	Dec 2000	A
6165187	Reger et al.	Dec 2000	A
6168594	Lafontaine et al.	Jan 2001	B1
6171321	Gifford, III et al.	Jan 2001	B1
6179832	Jones et al.	Jan 2001	B1
6179835	Panescu et al.	Jan 2001	B1
6179859	Bates et al.	Jan 2001	B1
6183468	Swanson et al.	Feb 2001	B1
6183486	Snow et al.	Feb 2001	B1
6190379	Heuser et al.	Feb 2001	B1
6191862	Swanson et al.	Feb 2001	B1
6197021	Panescu et al.	Mar 2001	B1
6200266	Shokrollahi et al.	Mar 2001	B1
6203537	Adrian	Mar 2001	B1
6203561	Ramee et al.	Mar 2001	B1
6210406	Webster	Apr 2001	B1
6211247	Goodman	Apr 2001	B1
6216044	Kordis	Apr 2001	B1
6216704	Ingle et al.	Apr 2001	B1
6217576	Tu et al.	Apr 2001	B1
6219577	Brown, III et al.	Apr 2001	B1
6228076	Winston et al.	May 2001	B1
6228109	Tu et al.	May 2001	B1
6231516	Keilman et al.	May 2001	B1
6231587	Makower	May 2001	B1
6235044	Root et al.	May 2001	B1
6236883	Ciaccio et al.	May 2001	B1
6237605	Vaska et al.	May 2001	B1
6238389	Paddock et al.	May 2001	B1
6238392	Long	May 2001	B1
6241666	Pomeranz et al.	Jun 2001	B1
6241753	Knowlton	Jun 2001	B1
6245020	Moore et al.	Jun 2001	B1
6245045	Stratienko	Jun 2001	B1
6248126	Lesser et al.	Jun 2001	B1
6251128	Knopp et al.	Jun 2001	B1
6258087	Edwards et al.	Jul 2001	B1
6273886	Edwards et al.	Aug 2001	B1
6280466	Kugler et al.	Aug 2001	B1
6283935	Laufer et al.	Sep 2001	B1
6283959	Lalonde et al.	Sep 2001	B1
6284743	Parmacek et al.	Sep 2001	B1
6287323	Hammerslag	Sep 2001	B1
6290696	Lafontaine	Sep 2001	B1
6292695	Webster, Jr. et al.	Sep 2001	B1
6293942	Goble et al.	Sep 2001	B1
6293943	Panescu et al.	Sep 2001	B1
6296619	Brisken et al.	Oct 2001	B1
6298256	Meyer	Oct 2001	B1
6299379	Lewis	Oct 2001	B1
6299623	Wulfman	Oct 2001	B1
6309379	Willard et al.	Oct 2001	B1
6309399	Barbut et al.	Oct 2001	B1
6311090	Knowlton	Oct 2001	B1
6317615	KenKnight et al.	Nov 2001	B1
6319242	Patterson et al.	Nov 2001	B1
6319251	Tu et al.	Nov 2001	B1
6322559	Daulton et al.	Nov 2001	B1
6325797	Stewart et al.	Dec 2001	B1
6325799	Goble	Dec 2001	B1
6328699	Eigler et al.	Dec 2001	B1
6346074	Roth	Feb 2002	B1
6346104	Daly et al.	Feb 2002	B2
6350248	Knudson et al.	Feb 2002	B1
6350276	Knowlton	Feb 2002	B1
6353751	Swanson et al.	Mar 2002	B1
6355029	Joye et al.	Mar 2002	B1
6357447	Swanson et al.	Mar 2002	B1
6361519	Knudson et al.	Mar 2002	B1
6364840	Crowley	Apr 2002	B1
6371965	Gifford, III et al.	Apr 2002	B2
6375668	Gifford et al.	Apr 2002	B1
6377854	Knowlton	Apr 2002	B1
6377855	Knowlton	Apr 2002	B1
6379352	Reynolds et al.	Apr 2002	B1
6379373	Sawhney et al.	Apr 2002	B1
6381497	Knowlton	Apr 2002	B1
6381498	Knowlton	Apr 2002	B1
6383151	Diederich et al.	May 2002	B1
6387105	Gifford, III et al.	May 2002	B1
6387380	Knowlton	May 2002	B1
6389311	Whayne et al.	May 2002	B1
6389314	Feiring	May 2002	B2
6391024	Sun et al.	May 2002	B1
6394096	Constantz	May 2002	B1
6394956	Chandrasekaran et al.	May 2002	B1
6398780	Farley et al.	Jun 2002	B1
6398782	Pecor et al.	Jun 2002	B1
6398792	O'Connor	Jun 2002	B1
6401720	Stevens et al.	Jun 2002	B1
6402719	Ponzi et al.	Jun 2002	B1
6405090	Knowlton	Jun 2002	B1
6409723	Edwards	Jun 2002	B1
6413255	Stern	Jul 2002	B1
6421559	Pearlman	Jul 2002	B1
6423057	He et al.	Jul 2002	B1
6425867	Vaezy et al.	Jul 2002	B1
6425912	Knowlton	Jul 2002	B1
6427089	Knowlton	Jul 2002	B1
6427118	Suzuki	Jul 2002	B1
6428534	Joye et al.	Aug 2002	B1
6428536	Panescu et al.	Aug 2002	B2
6430446	Knowlton	Aug 2002	B1
6432102	Joye et al.	Aug 2002	B2
6436056	Wang et al.	Aug 2002	B1
6438424	Knowlton	Aug 2002	B1
6440125	Rentrop	Aug 2002	B1
6442413	Silver	Aug 2002	B1
6443965	Gifford, III et al.	Sep 2002	B1
6445939	Swanson et al.	Sep 2002	B1
6447505	McGovern et al.	Sep 2002	B2
6447509	Bonnet et al.	Sep 2002	B1
6451034	Gifford, III et al.	Sep 2002	B1
6451044	Naghavi et al.	Sep 2002	B1
6453202	Knowlton	Sep 2002	B1
6454737	Nita et al.	Sep 2002	B1
6454757	Nita et al.	Sep 2002	B1
6454775	Demarais et al.	Sep 2002	B1
6458098	Kanesaka	Oct 2002	B1
6461378	Knowlton	Oct 2002	B1
6468276	McKay	Oct 2002	B1
6468297	Williams et al.	Oct 2002	B1
6470216	Knowlton	Oct 2002	B1
6470219	Edwards et al.	Oct 2002	B1
6471696	Berube et al.	Oct 2002	B1
6475213	Whayne et al.	Nov 2002	B1
6475215	Tanrisever	Nov 2002	B1
6475238	Fedida et al.	Nov 2002	B1
6477426	Fenn et al.	Nov 2002	B1
6480745	Nelson et al.	Nov 2002	B2
6481704	Koster et al.	Nov 2002	B1
6482202	Goble et al.	Nov 2002	B1
6484052	Visuri et al.	Nov 2002	B1
6485489	Teirstein et al.	Nov 2002	B2
6488679	Swanson et al.	Dec 2002	B1
6489307	Phillips et al.	Dec 2002	B1
6491705	Gifford, III et al.	Dec 2002	B2
6494891	Cornish et al.	Dec 2002	B1
6497711	Plaia et al.	Dec 2002	B1
6500172	Panescu et al.	Dec 2002	B1
6500174	Maguire et al.	Dec 2002	B1
6508765	Suorsa et al.	Jan 2003	B2
6508804	Sarge et al.	Jan 2003	B2
6508815	Strul et al.	Jan 2003	B1
6511478	Burnside et al.	Jan 2003	B1
6511496	Huter et al.	Jan 2003	B1
6511500	Rahme	Jan 2003	B1
6514236	Stratienko	Feb 2003	B1
6514245	Williams et al.	Feb 2003	B1
6514248	Eggers et al.	Feb 2003	B1
6517534	McGovern et al.	Feb 2003	B1
6517572	Kugler et al.	Feb 2003	B2
6522913	Swanson et al.	Feb 2003	B2
6522926	Kieval et al.	Feb 2003	B1
6524274	Rosenthal et al.	Feb 2003	B1
6524299	Tran et al.	Feb 2003	B1
6527765	Kelman et al.	Mar 2003	B2
6527769	Langberg et al.	Mar 2003	B2
6540761	Houser	Apr 2003	B2
6542781	Koblish et al.	Apr 2003	B1
6544780	Wang	Apr 2003	B1
6546272	MacKinnon et al.	Apr 2003	B1
6547788	Maguire et al.	Apr 2003	B1
6549800	Atalar et al.	Apr 2003	B1
6552796	Magnin et al.	Apr 2003	B2
6554780	Sampson et al.	Apr 2003	B1
6558381	Ingle et al.	May 2003	B2
6558382	Jahns et al.	May 2003	B2
6564096	Mest	May 2003	B2
6565582	Gifford, III et al.	May 2003	B2
6569109	Sakurai et al.	May 2003	B2
6569177	Dillard et al.	May 2003	B1
6570659	Schmitt	May 2003	B2
6572551	Smith et al.	Jun 2003	B1
6572612	Stewart et al.	Jun 2003	B2
6577902	Laufer et al.	Jun 2003	B1
6579308	Jansen et al.	Jun 2003	B1
6579311	Makower	Jun 2003	B1
6582423	Thapliyal et al.	Jun 2003	B1
6589238	Edwards et al.	Jul 2003	B2
6592526	Lenker	Jul 2003	B1
6592567	Levin et al.	Jul 2003	B1
6595959	Stratienko	Jul 2003	B1
6600956	Maschino et al.	Jul 2003	B2
6602242	Fung	Aug 2003	B1
6602246	Joye et al.	Aug 2003	B1
6605061	Van Tassel et al.	Aug 2003	B2
6605084	Acker et al.	Aug 2003	B2
6623452	Chien et al.	Sep 2003	B2
6623453	Guibert et al.	Sep 2003	B1
6632193	Davison et al.	Oct 2003	B1
6632196	Houser	Oct 2003	B1
6640120	Swanson et al.	Oct 2003	B1
6645223	Boyle et al.	Nov 2003	B2
6648854	Patterson et al.	Nov 2003	B1
6648878	Lafontaine	Nov 2003	B2
6648879	Joye et al.	Nov 2003	B2
6651672	Roth	Nov 2003	B2
6652513	Panescu et al.	Nov 2003	B2
6652515	Maguire et al.	Nov 2003	B1
6656136	Weng et al.	Dec 2003	B1
6658279	Swanson et al.	Dec 2003	B2
6659981	Stewart et al.	Dec 2003	B2
6666858	Lafontaine	Dec 2003	B2
6666863	Wentzel et al.	Dec 2003	B2
6669655	Acker et al.	Dec 2003	B1
6669692	Nelson et al.	Dec 2003	B1
6673040	Samson et al.	Jan 2004	B1
6673064	Rentrop	Jan 2004	B1
6673066	Werneth	Jan 2004	B2
6673090	Root et al.	Jan 2004	B2
6673101	Fitzgerald et al.	Jan 2004	B1
6673290	Whayne et al.	Jan 2004	B1
6676678	Gifford, III et al.	Jan 2004	B2
6679268	Stevens et al.	Jan 2004	B2
6681773	Murphy et al.	Jan 2004	B2
6682541	Gifford, III et al.	Jan 2004	B1
6684098	Oshio et al.	Jan 2004	B2
6685732	Kramer	Feb 2004	B2
6685733	Dae et al.	Feb 2004	B1
6689086	Nita et al.	Feb 2004	B1
6689148	Sawhney et al.	Feb 2004	B2
6690181	Dowdeswell et al.	Feb 2004	B1
6692490	Edwards	Feb 2004	B1
6695830	Vigil et al.	Feb 2004	B2
6695857	Gifford, III et al.	Feb 2004	B2
6699241	Rappaport et al.	Mar 2004	B2
6699257	Gifford, III et al.	Mar 2004	B2
6702748	Nita et al.	Mar 2004	B1
6702811	Stewart et al.	Mar 2004	B2
6706010	Miki et al.	Mar 2004	B1
6706011	Murphy-Chutorian et al.	Mar 2004	B1
6706037	Zvuloni et al.	Mar 2004	B2
6709431	Lafontaine	Mar 2004	B2
6711429	Gilboa et al.	Mar 2004	B1
6712815	Sampson et al.	Mar 2004	B2
6714822	King et al.	Mar 2004	B2
6716184	Vaezy et al.	Apr 2004	B2
6720350	Kunz et al.	Apr 2004	B2
6723043	Kleeman et al.	Apr 2004	B2
6723064	Babaev	Apr 2004	B2
6736811	Panescu et al.	May 2004	B2
6743184	Sampson et al.	Jun 2004	B2
6746401	Panescu	Jun 2004	B2
6746464	Makower	Jun 2004	B1
6746474	Saadat	Jun 2004	B2
6748953	Sherry et al.	Jun 2004	B2
6749607	Edwards et al.	Jun 2004	B2
6752805	Maguire et al.	Jun 2004	B2
6760616	Hoey et al.	Jul 2004	B2
6763261	Casscells, III et al.	Jul 2004	B2
6764501	Ganz	Jul 2004	B2
6769433	Zikorus et al.	Aug 2004	B2
6770070	Balbierz	Aug 2004	B1
6771996	Bowe et al.	Aug 2004	B2
6773433	Stewart et al.	Aug 2004	B2
6786900	Joye et al.	Sep 2004	B2
6786901	Joye et al.	Sep 2004	B2
6786904	Döscher et al.	Sep 2004	B2
6788977	Fenn et al.	Sep 2004	B2
6790206	Panescu	Sep 2004	B2
6790222	Kugler et al.	Sep 2004	B2
6796981	Wham et al.	Sep 2004	B2
6797933	Mendis et al.	Sep 2004	B1
6797960	Spartiotis et al.	Sep 2004	B1
6800075	Mische et al.	Oct 2004	B2
6802857	Walsh et al.	Oct 2004	B1
6807444	Tu et al.	Oct 2004	B2
6811550	Holland et al.	Nov 2004	B2
6813520	Truckai et al.	Nov 2004	B2
6814730	Li	Nov 2004	B2
6814733	Schwartz et al.	Nov 2004	B2
6823205	Jara	Nov 2004	B1
6824516	Batten et al.	Nov 2004	B2
6827726	Parodi	Dec 2004	B2
6827926	Robinson et al.	Dec 2004	B2
6829497	Mogul	Dec 2004	B2
6830568	Kesten et al.	Dec 2004	B1
6837886	Collins et al.	Jan 2005	B2
6837888	Ciarrocca et al.	Jan 2005	B2
6845267	Harrison	Jan 2005	B2
6847848	Sterzer	Jan 2005	B2
6849073	Hoey et al.	Feb 2005	B2
6849075	Bertolero et al.	Feb 2005	B2
6853425	Kim et al.	Feb 2005	B2
6855123	Nita	Feb 2005	B2
6855143	Davison	Feb 2005	B2
6869431	Maguire et al.	Mar 2005	B2
6872183	Sampson et al.	Mar 2005	B2
6884260	Kugler et al.	Apr 2005	B2
6889694	Hooven	May 2005	B2
6893436	Woodard et al.	May 2005	B2
6895077	Karellas et al.	May 2005	B2
6895265	Silver	May 2005	B2
6898454	Atalar et al.	May 2005	B2
6899711	Stewart et al.	May 2005	B2
6899718	Gifford, III et al.	May 2005	B2
6905494	Yon et al.	Jun 2005	B2
6908462	Joye et al.	Jun 2005	B2
6909009	Koridze	Jun 2005	B2
6911026	Hall et al.	Jun 2005	B1
6915806	Pacek et al.	Jul 2005	B2
6923805	LaFontaine et al.	Aug 2005	B1
6926246	Ginggen	Aug 2005	B2
6926713	Rioux et al.	Aug 2005	B2
6926716	Baker et al.	Aug 2005	B2
6929009	Makower et al.	Aug 2005	B2
6929632	Nita et al.	Aug 2005	B2
6929639	Lafontaine	Aug 2005	B2
6932776	Carr	Aug 2005	B2
6936047	Nasab et al.	Aug 2005	B2
6942620	Nita et al.	Sep 2005	B2
6942657	Sinofsky et al.	Sep 2005	B2
6942677	Nita et al.	Sep 2005	B2
6942692	Landau et al.	Sep 2005	B2
6949097	Stewart et al.	Sep 2005	B2
6949121	Laguna	Sep 2005	B1
6952615	Satake	Oct 2005	B2
6953425	Brister	Oct 2005	B2
6955174	Joye et al.	Oct 2005	B2
6955175	Stevens et al.	Oct 2005	B2
6958075	Mon et al.	Oct 2005	B2
6959711	Murphy et al.	Nov 2005	B2
6960207	Vanney et al.	Nov 2005	B2
6962584	Stone et al.	Nov 2005	B1
6964660	Maguire et al.	Nov 2005	B2
6966908	Maguire et al.	Nov 2005	B2
6972015	Joye et al.	Dec 2005	B2
6972024	Kilpatrick et al.	Dec 2005	B1
6974456	Edwards et al.	Dec 2005	B2
6978174	Gelfand et al.	Dec 2005	B2
6979329	Burnside et al.	Dec 2005	B2
6979420	Weber	Dec 2005	B2
6984238	Gifford, III et al.	Jan 2006	B2
6985774	Kieval et al.	Jan 2006	B2
6986739	Warren et al.	Jan 2006	B2
6989009	Lafontaine	Jan 2006	B2
6989010	Francischelli et al.	Jan 2006	B2
6991617	Hektner et al.	Jan 2006	B2
7001378	Yon et al.	Feb 2006	B2
7006858	Silver et al.	Feb 2006	B2
7008667	Chudzik et al.	Mar 2006	B2
7011508	Lum	Mar 2006	B2
7022105	Edwards	Apr 2006	B1
7022120	Lafontaine	Apr 2006	B2
7025767	Schaefer et al.	Apr 2006	B2
7033322	Silver	Apr 2006	B2
7033372	Cahalan	Apr 2006	B1
7041098	Farley et al.	May 2006	B2
7050848	Hoey et al.	May 2006	B2
7063670	Sampson et al.	Jun 2006	B2
7063679	Maguire et al.	Jun 2006	B2
7063719	Jansen et al.	Jun 2006	B2
7066895	Podany	Jun 2006	B2
7066900	Botto et al.	Jun 2006	B2
7066904	Rosenthal et al.	Jun 2006	B2
7072720	Puskas	Jul 2006	B2
7074217	Strul et al.	Jul 2006	B2
7081112	Joye et al.	Jul 2006	B2
7081114	Rashidi	Jul 2006	B2
7083614	Fjield et al.	Aug 2006	B2
7084276	Vu et al.	Aug 2006	B2
7087026	Callister et al.	Aug 2006	B2
7087051	Bourne et al.	Aug 2006	B2
7087052	Sampson et al.	Aug 2006	B2
7087053	Vanney	Aug 2006	B2
7089065	Westlund et al.	Aug 2006	B2
7097641	Arless et al.	Aug 2006	B1
7100614	Stevens et al.	Sep 2006	B2
7101368	Lafontaine	Sep 2006	B2
7104983	Grasso, III et al.	Sep 2006	B2
7104987	Biggs et al.	Sep 2006	B2
7108715	Lawrence-Brown et al.	Sep 2006	B2
7112196	Brosch et al.	Sep 2006	B2
7112198	Satake	Sep 2006	B2
7112211	Gifford, III et al.	Sep 2006	B2
7122019	Kesten et al.	Oct 2006	B1
7122033	Wood	Oct 2006	B2
7134438	Makower et al.	Nov 2006	B2
7137963	Nita et al.	Nov 2006	B2
7137980	Buysse et al.	Nov 2006	B2
7153315	Miller	Dec 2006	B2
7155271	Halperin et al.	Dec 2006	B2
7157491	Mewshaw et al.	Jan 2007	B2
7157492	Mewshaw et al.	Jan 2007	B2
7158832	Kieval et al.	Jan 2007	B2
7160296	Pearson et al.	Jan 2007	B2
7162303	Levin et al.	Jan 2007	B2
7165551	Edwards et al.	Jan 2007	B2
7169144	Hoey et al.	Jan 2007	B2
7172589	Lafontaine	Feb 2007	B2
7172610	Heitzmann et al.	Feb 2007	B2
7181261	Silver et al.	Feb 2007	B2
7184811	Phan et al.	Feb 2007	B2
7184827	Edwards	Feb 2007	B1
7189227	Lafontaine	Mar 2007	B2
7192427	Chapelon et al.	Mar 2007	B2
7192586	Bander	Mar 2007	B2
7197354	Sobe	Mar 2007	B2
7198632	Lim et al.	Apr 2007	B2
7200445	Dalbec et al.	Apr 2007	B1
7201749	Govari et al.	Apr 2007	B2
7203537	Mower	Apr 2007	B2
7214234	Rapacki et al.	May 2007	B2
7220233	Nita et al.	May 2007	B2
7220239	Wilson et al.	May 2007	B2
7220257	Lafontaine	May 2007	B1
7220270	Sawhney et al.	May 2007	B2
7232458	Saadat	Jun 2007	B2
7232459	Greenberg et al.	Jun 2007	B2
7238184	Megerman et al.	Jul 2007	B2
7241273	Maguire et al.	Jul 2007	B2
7241736	Hunter et al.	Jul 2007	B2
7247141	Makin et al.	Jul 2007	B2
7250041	Chiu et al.	Jul 2007	B2
7250440	Mewshaw et al.	Jul 2007	B2
7252664	Nasab et al.	Aug 2007	B2
7252679	Fischell et al.	Aug 2007	B2
7264619	Venturelli	Sep 2007	B2
7279600	Mewshaw et al.	Oct 2007	B2
7280863	Shachar	Oct 2007	B2
7282213	Schroeder et al.	Oct 2007	B2
7285119	Stewart et al.	Oct 2007	B2
7285120	Im et al.	Oct 2007	B2
7288089	Yon et al.	Oct 2007	B2
7288096	Chin	Oct 2007	B2
7291146	Steinke et al.	Nov 2007	B2
7293562	Malecki et al.	Nov 2007	B2
7294125	Phalen et al.	Nov 2007	B2
7294126	Sampson et al.	Nov 2007	B2
7294127	Leung et al.	Nov 2007	B2
7297131	Nita	Nov 2007	B2
7297475	Koiwai et al.	Nov 2007	B2
7300433	Lane et al.	Nov 2007	B2
7301108	Egitto et al.	Nov 2007	B2
7310150	Guillermo et al.	Dec 2007	B2
7313430	Urquhart et al.	Dec 2007	B2
7314483	Landau et al.	Jan 2008	B2
7317077	Averback et al.	Jan 2008	B2
7323006	Andreas et al.	Jan 2008	B2
7326206	Paul et al.	Feb 2008	B2
7326226	Root et al.	Feb 2008	B2
7326235	Edwards	Feb 2008	B2
7326237	DePalma et al.	Feb 2008	B2
7329236	Kesten et al.	Feb 2008	B2
7335180	Nita et al.	Feb 2008	B2
7335192	Keren et al.	Feb 2008	B2
7338467	Lutter	Mar 2008	B2
7341570	Keren et al.	Mar 2008	B2
7343195	Strommer et al.	Mar 2008	B2
7347857	Anderson et al.	Mar 2008	B2
7348003	Salcedo et al.	Mar 2008	B2
7352593	Zeng et al.	Apr 2008	B2
7354927	Vu	Apr 2008	B2
7359732	Kim et al.	Apr 2008	B2
7361341	Salcedo et al.	Apr 2008	B2
7364566	Elkins et al.	Apr 2008	B2
7367970	Govari et al.	May 2008	B2
7367975	Malecki et al.	May 2008	B2
7371231	Rioux et al.	May 2008	B2
7387126	Cox et al.	Jun 2008	B2
7393338	Nita	Jul 2008	B2
7396355	Goldman et al.	Jul 2008	B2
7402151	Rosenman et al.	Jul 2008	B2
7402312	Rosen et al.	Jul 2008	B2
7404824	Webler et al.	Jul 2008	B1
7406970	Zikorus et al.	Aug 2008	B2
7407502	Strul et al.	Aug 2008	B2
7407506	Makower	Aug 2008	B2
7407671	McBride et al.	Aug 2008	B2
7408021	Averback et al.	Aug 2008	B2
7410486	Fuimaono et al.	Aug 2008	B2
7413556	Zhang et al.	Aug 2008	B2
7425212	Danek et al.	Sep 2008	B1
7426409	Casscells, III et al.	Sep 2008	B2
7435248	Taimisto et al.	Oct 2008	B2
7447453	Kim et al.	Nov 2008	B2
7449018	Kramer	Nov 2008	B2
7452538	Ni et al.	Nov 2008	B2
7473890	Grier et al.	Jan 2009	B2
7476384	Ni et al.	Jan 2009	B2
7479157	Weber et al.	Jan 2009	B2
7481803	Kesten et al.	Jan 2009	B2
7485104	Kieval	Feb 2009	B2
7486805	Krattiger	Feb 2009	B2
7487780	Hooven	Feb 2009	B2
7493154	Bonner et al.	Feb 2009	B2
7494485	Beck et al.	Feb 2009	B2
7494486	Mische et al.	Feb 2009	B2
7494488	Weber	Feb 2009	B2
7494661	Sanders	Feb 2009	B2
7495439	Wiggins	Feb 2009	B2
7497858	Chapelon et al.	Mar 2009	B2
7499745	Littrup et al.	Mar 2009	B2
7500985	Saadat	Mar 2009	B2
7505812	Eggers et al.	Mar 2009	B1
7505816	Schmeling et al.	Mar 2009	B2
7507233	Littrup et al.	Mar 2009	B2
7507235	Keogh et al.	Mar 2009	B2
7511494	Wedeen	Mar 2009	B2
7512445	Truckai et al.	Mar 2009	B2
7527643	Case et al.	May 2009	B2
7529589	Williams et al.	May 2009	B2
7540852	Nita et al.	Jun 2009	B2
7540870	Babaev	Jun 2009	B2
RE40863	Tay et al.	Jul 2009	E
7556624	Laufer et al.	Jul 2009	B2
7558625	Levin et al.	Jul 2009	B2
7563247	Maguire et al.	Jul 2009	B2
7566319	McAuley et al.	Jul 2009	B2
7569052	Phan et al.	Aug 2009	B2
7582111	Krolik et al.	Sep 2009	B2
7584004	Caparso et al.	Sep 2009	B2
7585835	Hill et al.	Sep 2009	B2
7591996	Hwang et al.	Sep 2009	B2
7597704	Frazier et al.	Oct 2009	B2
7598228	Hattori et al.	Oct 2009	B2
7599730	Hunter et al.	Oct 2009	B2
7603166	Casscells, III et al.	Oct 2009	B2
7604608	Nita et al.	Oct 2009	B2
7604633	Truckai et al.	Oct 2009	B2
7615015	Coleman	Nov 2009	B2
7615072	Rust et al.	Nov 2009	B2
7617005	Demarais et al.	Nov 2009	B2
7620451	Demarais et al.	Nov 2009	B2
7621902	Nita et al.	Nov 2009	B2
7621929	Nita et al.	Nov 2009	B2
7626015	Feinstein et al.	Dec 2009	B2
7626235	Kinoshita	Dec 2009	B2
7632268	Edwards et al.	Dec 2009	B2
7632845	Vu et al.	Dec 2009	B2
7635383	Gumm	Dec 2009	B2
7640046	Pastore et al.	Dec 2009	B2
7641633	Laufer et al.	Jan 2010	B2
7641679	Joye et al.	Jan 2010	B2
7646544	Batchko et al.	Jan 2010	B2
7647115	Levin et al.	Jan 2010	B2
7653438	Deem et al.	Jan 2010	B2
7655006	Sauvageau et al.	Feb 2010	B2
7662114	Seip et al.	Feb 2010	B2
7664548	Amurthur et al.	Feb 2010	B2
7670279	Gertner	Mar 2010	B2
7670335	Keidar	Mar 2010	B2
7671084	Mewshaw et al.	Mar 2010	B2
7678104	Keidar	Mar 2010	B2
7678106	Lee	Mar 2010	B2
7678108	Chrisitian et al.	Mar 2010	B2
7691080	Seward et al.	Apr 2010	B2
7699809	Urmey	Apr 2010	B2
7706882	Francischelli et al.	Apr 2010	B2
7715912	Rezai et al.	May 2010	B2
7717853	Nita	May 2010	B2
7717909	Strul et al.	May 2010	B2
7717948	Demarais et al.	May 2010	B2
7722539	Carter et al.	May 2010	B2
7725157	Dumoulin et al.	May 2010	B2
7727178	Wilson et al.	Jun 2010	B2
7736317	Stephens et al.	Jun 2010	B2
7736360	Mody et al.	Jun 2010	B2
7736362	Eberl et al.	Jun 2010	B2
7738952	Yun et al.	Jun 2010	B2
7740629	Anderson et al.	Jun 2010	B2
7741299	Feinstein et al.	Jun 2010	B2
7742795	Stone et al.	Jun 2010	B2
7744594	Yamazaki et al.	Jun 2010	B2
7753907	DiMatteo et al.	Jul 2010	B2
7756583	Demarais et al.	Jul 2010	B2
7758510	Nita et al.	Jul 2010	B2
7758520	Griffin et al.	Jul 2010	B2
7759315	Cuzzocrea et al.	Jul 2010	B2
7766833	Lee et al.	Aug 2010	B2
7766878	Tremaglio, Jr. et al.	Aug 2010	B2
7766892	Keren et al.	Aug 2010	B2
7767844	Lee et al.	Aug 2010	B2
7769427	Shachar	Aug 2010	B2
7771372	Wilson	Aug 2010	B2
7771421	Stewart et al.	Aug 2010	B2
7776967	Perry et al.	Aug 2010	B2
7777486	Hargreaves et al.	Aug 2010	B2
7780660	Bourne et al.	Aug 2010	B2
7789876	Zikorus et al.	Sep 2010	B2
7792568	Zhong et al.	Sep 2010	B2
7799021	Leung et al.	Sep 2010	B2
7803168	Gifford et al.	Sep 2010	B2
7806871	Li et al.	Oct 2010	B2
7811265	Hering et al.	Oct 2010	B2
7811281	Rentrop	Oct 2010	B1
7811313	Mon et al.	Oct 2010	B2
7816511	Kawashima et al.	Oct 2010	B2
7818053	Kassab	Oct 2010	B2
7819866	Bednarek	Oct 2010	B2
7822460	Halperin et al.	Oct 2010	B2
7828837	Khoury	Nov 2010	B2
7832407	Gertner	Nov 2010	B2
7833220	Mon et al.	Nov 2010	B2
7837676	Sinelnikov et al.	Nov 2010	B2
7837720	Mon	Nov 2010	B2
7841978	Gertner	Nov 2010	B2
7846157	Kozel	Dec 2010	B2
7846160	Payne et al.	Dec 2010	B2
7846172	Makower	Dec 2010	B2
7849860	Makower et al.	Dec 2010	B2
7850685	Kunis et al.	Dec 2010	B2
7853333	Demarais	Dec 2010	B2
7854734	Biggs et al.	Dec 2010	B2
7857756	Warren et al.	Dec 2010	B2
7862565	Eder et al.	Jan 2011	B2
7863897	Slocum, Jr. et al.	Jan 2011	B2
7869854	Shachar et al.	Jan 2011	B2
7873417	Demarais et al.	Jan 2011	B2
7887538	Bleich et al.	Feb 2011	B2
7894905	Pless et al.	Feb 2011	B2
7896873	Hiller et al.	Mar 2011	B2
7901400	Wham et al.	Mar 2011	B2
7901402	Jones et al.	Mar 2011	B2
7901420	Dunn	Mar 2011	B2
7905862	Sampson	Mar 2011	B2
7918850	Govari et al.	Apr 2011	B2
7927370	Webler et al.	Apr 2011	B2
7937143	Demarais et al.	May 2011	B2
7938830	Saadat et al.	May 2011	B2
7942874	Eder et al.	May 2011	B2
7942928	Webler et al.	May 2011	B2
7946976	Gertner	May 2011	B2
7950397	Thapliyal et al.	May 2011	B2
7955293	Nita et al.	Jun 2011	B2
7956613	Wald	Jun 2011	B2
7959627	Utley et al.	Jun 2011	B2
7962854	Vance et al.	Jun 2011	B2
7967782	Laufer et al.	Jun 2011	B2
7967808	Fitzgerald et al.	Jun 2011	B2
7972327	Eberl et al.	Jul 2011	B2
7972330	Alejandro et al.	Jul 2011	B2
7983751	Zdeblick et al.	Jul 2011	B2
8001976	Gertner	Aug 2011	B2
8007440	Magnin et al.	Aug 2011	B2
8012147	Lafontaine	Sep 2011	B2
8019435	Hastings et al.	Sep 2011	B2
8021362	Deem et al.	Sep 2011	B2
8021413	Dierking et al.	Sep 2011	B2
8025661	Arnold et al.	Sep 2011	B2
8027718	Spinner et al.	Sep 2011	B2
8031927	Karl et al.	Oct 2011	B2
8033284	Porter et al.	Oct 2011	B2
8048144	Thistle et al.	Nov 2011	B2
8052636	Moll et al.	Nov 2011	B2
8052700	Dunn	Nov 2011	B2
8062289	Babaev	Nov 2011	B2
8075580	Makower	Dec 2011	B2
8080006	Lafontaine et al.	Dec 2011	B2
8088127	Mayse et al.	Jan 2012	B2
8116883	Williams et al.	Feb 2012	B2
8119183	O'Donoghue et al.	Feb 2012	B2
8120518	Jang et al.	Feb 2012	B2
8123741	Marrouche et al.	Feb 2012	B2
8128617	Bencini et al.	Mar 2012	B2
8131371	Demarals et al.	Mar 2012	B2
8131372	Levin et al.	Mar 2012	B2
8131382	Asada	Mar 2012	B2
8137274	Weng et al.	Mar 2012	B2
8140170	Rezai et al.	Mar 2012	B2
8143316	Ueno	Mar 2012	B2
8145316	Deem et al.	Mar 2012	B2
8145317	Demarais et al.	Mar 2012	B2
8150518	Levin et al.	Apr 2012	B2
8150519	Demarais et al.	Apr 2012	B2
8150520	Demarais et al.	Apr 2012	B2
8152830	Gumm	Apr 2012	B2
8162933	Francischelli et al.	Apr 2012	B2
8175711	Demarais et al.	May 2012	B2
8187261	Watson	May 2012	B2
8190238	Moll et al.	May 2012	B2
8192053	Owen et al.	Jun 2012	B2
8198611	LaFontaine et al.	Jun 2012	B2
8214056	Hoffer et al.	Jul 2012	B2
8221407	Phan et al.	Jul 2012	B2
8226637	Satake	Jul 2012	B2
8231617	Satake	Jul 2012	B2
8241217	Chiang et al.	Aug 2012	B2
8257724	Cromack et al.	Sep 2012	B2
8257725	Cromack et al.	Sep 2012	B2
8260397	Ruff et al.	Sep 2012	B2
8263104	Ho et al.	Sep 2012	B2
8273023	Razavi	Sep 2012	B2
8277379	Lau et al.	Oct 2012	B2
8287524	Siegel	Oct 2012	B2
8287532	Carroll et al.	Oct 2012	B2
8292881	Brannan et al.	Oct 2012	B2
8293703	Averback et al.	Oct 2012	B2
8295902	Salahieh et al.	Oct 2012	B2
8295912	Gertner	Oct 2012	B2
8308722	Ormsby et al.	Nov 2012	B2
8317776	Ferren et al.	Nov 2012	B2
8317810	Stangenes et al.	Nov 2012	B2
8329179	Ni et al.	Dec 2012	B2
8336705	Okahisa	Dec 2012	B2
8343031	Gertner	Jan 2013	B2
8343145	Brannan	Jan 2013	B2
8347891	Demarais et al.	Jan 2013	B2
8353945	Andreas et al.	Jan 2013	B2
8364237	Stone et al.	Jan 2013	B2
8366615	Razavi	Feb 2013	B2
8382697	Brenneman et al.	Feb 2013	B2
8388680	Starksen et al.	Mar 2013	B2
8396548	Perry et al.	Mar 2013	B2
8398629	Thistle	Mar 2013	B2
8401667	Gustus et al.	Mar 2013	B2
8403881	Ferren et al.	Mar 2013	B2
8406877	Smith et al.	Mar 2013	B2
8409172	Moll et al.	Apr 2013	B2
8409193	Young et al.	Apr 2013	B2
8409195	Young	Apr 2013	B2
8418362	Zerfas et al.	Apr 2013	B2
8452988	Wang	May 2013	B2
8454594	Demarais et al.	Jun 2013	B2
8460358	Andreas et al.	Jun 2013	B2
8465452	Kassab	Jun 2013	B2
8469919	Ingle et al.	Jun 2013	B2
8473067	Hastings et al.	Jun 2013	B2
8480663	Ingle et al.	Jul 2013	B2
8485992	Griffin et al.	Jul 2013	B2
8486060	Kotmel et al.	Jul 2013	B2
8486063	Werneth et al.	Jul 2013	B2
8488591	Miali et al.	Jul 2013	B2
20010007070	Stewart et al.	Jul 2001	A1
20010039419	Francischelli et al.	Nov 2001	A1
20010051774	Littrup et al.	Dec 2001	A1
20020004631	Jenkins et al.	Jan 2002	A1
20020022864	Mahvi et al.	Feb 2002	A1
20020042639	Murphy-Chutorian et al.	Apr 2002	A1
20020045811	Kittrell et al.	Apr 2002	A1
20020045890	Celliers et al.	Apr 2002	A1
20020062123	McClurken et al.	May 2002	A1
20020062146	Makower et al.	May 2002	A1
20020065542	Lax et al.	May 2002	A1
20020072686	Hoey et al.	Jun 2002	A1
20020077592	Barry	Jun 2002	A1
20020082552	Ding et al.	Jun 2002	A1
20020087151	Mody et al.	Jul 2002	A1
20020087156	Maguire et al.	Jul 2002	A1
20020091381	Edwards	Jul 2002	A1
20020095197	Lardo et al.	Jul 2002	A1
20020107511	Collins et al.	Aug 2002	A1
20020107536	Hussein	Aug 2002	A1
20020111618	Stewart et al.	Aug 2002	A1
20020143324	Edwards	Oct 2002	A1
20020147480	Mamayek	Oct 2002	A1
20020169444	Mest et al.	Nov 2002	A1
20020198520	Coen et al.	Dec 2002	A1
20030004510	Wham et al.	Jan 2003	A1
20030028114	Casscells, III et al.	Feb 2003	A1
20030050635	Truckai et al.	Mar 2003	A1
20030060857	Perrson et al.	Mar 2003	A1
20030060858	Kieval et al.	Mar 2003	A1
20030065317	Rudie et al.	Apr 2003	A1
20030069619	Fenn et al.	Apr 2003	A1
20030088189	Tu et al.	May 2003	A1
20030092995	Thompson	May 2003	A1
20030114791	Rosenthal et al.	Jun 2003	A1
20030139689	Shturman et al.	Jul 2003	A1
20030195501	Sherman et al.	Oct 2003	A1
20030199747	Michlitsch et al.	Oct 2003	A1
20030212394	Pearson et al.	Nov 2003	A1
20030220639	Chapelon et al.	Nov 2003	A1
20030229340	Sherry et al.	Dec 2003	A1
20030229384	Mon	Dec 2003	A1
20040000633	Casper et al.	Jan 2004	A1
20040006359	Laguna	Jan 2004	A1
20040010118	Zerhusen et al.	Jan 2004	A1
20040019348	Stevens et al.	Jan 2004	A1
20040024371	Plicchi et al.	Feb 2004	A1
20040043030	Griffiths et al.	Mar 2004	A1
20040062852	Schroeder et al.	Apr 2004	A1
20040064090	Keren et al.	Apr 2004	A1
20040064093	Hektner et al.	Apr 2004	A1
20040073206	Foley et al.	Apr 2004	A1
20040088002	Boyle et al.	May 2004	A1
20040093055	Bartorelli et al.	May 2004	A1
20040106871	Hunyor et al.	Jun 2004	A1
20040111016	Casscells, III et al.	Jun 2004	A1
20040117032	Roth	Jun 2004	A1
20040122421	Wood	Jun 2004	A1
20040147915	Hasebe	Jul 2004	A1
20040162555	Farley et al.	Aug 2004	A1
20040167506	Chen	Aug 2004	A1
20040181165	Hoey et al.	Sep 2004	A1
20040186356	O'Malley et al.	Sep 2004	A1
20040186468	Edwards	Sep 2004	A1
20040187875	He et al.	Sep 2004	A1
20040193211	Voegele et al.	Sep 2004	A1
20040220556	Cooper et al.	Nov 2004	A1
20040243022	Carney et al.	Dec 2004	A1
20040243199	Mon et al.	Dec 2004	A1
20040253304	Gross et al.	Dec 2004	A1
20040267250	Yon et al.	Dec 2004	A1
20050010095	Stewart et al.	Jan 2005	A1
20050010208	Winston et al.	Jan 2005	A1
20050015125	Mioduski et al.	Jan 2005	A1
20050033136	Govari et al.	Feb 2005	A1
20050080374	Esch et al.	Apr 2005	A1
20050090820	Cornelius et al.	Apr 2005	A1
20050096647	Steinke et al.	May 2005	A1
20050129616	Salcedo et al.	Jun 2005	A1
20050137180	Robinson et al.	Jun 2005	A1
20050143817	Hunter et al.	Jun 2005	A1
20050148842	Wang et al.	Jul 2005	A1
20050149069	Bertolero et al.	Jul 2005	A1
20050149080	Hunter et al.	Jul 2005	A1
20050149158	Hunter et al.	Jul 2005	A1
20050149173	Hunter et al.	Jul 2005	A1
20050149175	Hunter et al.	Jul 2005	A1
20050154277	Tang et al.	Jul 2005	A1
20050154445	Hunter et al.	Jul 2005	A1
20050154453	Hunter et al.	Jul 2005	A1
20050154454	Hunter et al.	Jul 2005	A1
20050165389	Swain et al.	Jul 2005	A1
20050165391	Maguire et al.	Jul 2005	A1
20050165467	Hunter et al.	Jul 2005	A1
20050165488	Hunter et al.	Jul 2005	A1
20050175661	Hunter et al.	Aug 2005	A1
20050175662	Hunter et al.	Aug 2005	A1
20050175663	Hunter et al.	Aug 2005	A1
20050177103	Hunter et al.	Aug 2005	A1
20050177225	Hunter et al.	Aug 2005	A1
20050181004	Hunter et al.	Aug 2005	A1
20050181008	Hunter et al.	Aug 2005	A1
20050181011	Hunter et al.	Aug 2005	A1
20050181977	Hunter et al.	Aug 2005	A1
20050182479	Bonsignore et al.	Aug 2005	A1
20050183728	Hunter et al.	Aug 2005	A1
20050186242	Hunter et al.	Aug 2005	A1
20050186243	Hunter et al.	Aug 2005	A1
20050191331	Hunter et al.	Sep 2005	A1
20050203410	Jenkins	Sep 2005	A1
20050203434	Kassab	Sep 2005	A1
20050203498	Mon et al.	Sep 2005	A1
20050209587	Joye et al.	Sep 2005	A1
20050214205	Salcedo et al.	Sep 2005	A1
20050214207	Salcedo et al.	Sep 2005	A1
20050214208	Salcedo et al.	Sep 2005	A1
20050214209	Salcedo et al.	Sep 2005	A1
20050214210	Salcedo et al.	Sep 2005	A1
20050214268	Cavanagh et al.	Sep 2005	A1
20050228286	Messerly et al.	Oct 2005	A1
20050228415	Gertner	Oct 2005	A1
20050228460	Levin et al.	Oct 2005	A1
20050232921	Rosen et al.	Oct 2005	A1
20050234312	Suzuki et al.	Oct 2005	A1
20050245862	Seward	Nov 2005	A1
20050251116	Steinke et al.	Nov 2005	A1
20050252553	Ginggen	Nov 2005	A1
20050256398	Hastings et al.	Nov 2005	A1
20050267556	Shuros et al.	Dec 2005	A1
20050283195	Pastore et al.	Dec 2005	A1
20060004323	Chang et al.	Jan 2006	A1
20060018949	Ammon et al.	Jan 2006	A1
20060024564	Manclaw	Feb 2006	A1
20060025765	Landman et al.	Feb 2006	A1
20060062786	Salcedo et al.	Mar 2006	A1
20060083194	Dhrimaj et al.	Apr 2006	A1
20060085054	Zikorus et al.	Apr 2006	A1
20060089637	Werneth et al.	Apr 2006	A1
20060089638	Carmel et al.	Apr 2006	A1
20060095096	DeBenedictis et al.	May 2006	A1
20060106375	Werneth et al.	May 2006	A1
20060142790	Gertner	Jun 2006	A1
20060147492	Hunter et al.	Jul 2006	A1
20060149166	Zvuloni	Jul 2006	A1
20060167106	Zhang et al.	Jul 2006	A1
20060167498	DiLorenzo	Jul 2006	A1
20060171895	Bucay-Couto	Aug 2006	A1
20060184060	Belalcazar et al.	Aug 2006	A1
20060184221	Stewart et al.	Aug 2006	A1
20060195139	Gertner	Aug 2006	A1
20060206150	Demarais et al.	Sep 2006	A1
20060224153	Fischell et al.	Oct 2006	A1
20060235286	Stone et al.	Oct 2006	A1
20060239921	Mangat et al.	Oct 2006	A1
20060240070	Cromack et al.	Oct 2006	A1
20060246143	Ege	Nov 2006	A1
20060247266	Yamada et al.	Nov 2006	A1
20060247760	Ganesan et al.	Nov 2006	A1
20060263393	Demopulos et al.	Nov 2006	A1
20060269555	Salcedo et al.	Nov 2006	A1
20060271111	Demarais et al.	Nov 2006	A1
20060280858	Kokish	Dec 2006	A1
20060287644	Inganas et al.	Dec 2006	A1
20070016184	Cropper et al.	Jan 2007	A1
20070016274	Boveja et al.	Jan 2007	A1
20070027390	Maschke et al.	Feb 2007	A1
20070043077	Mewshaw et al.	Feb 2007	A1
20070043409	Brian et al.	Feb 2007	A1
20070049924	Rahn	Mar 2007	A1
20070066972	Ormsby et al.	Mar 2007	A1
20070073151	Lee	Mar 2007	A1
20070078498	Rezai et al.	Apr 2007	A1
20070093710	Maschke	Apr 2007	A1
20070100405	Thompson et al.	May 2007	A1
20070106247	Burnett et al.	May 2007	A1
20070112327	Yun et al.	May 2007	A1
20070118107	Francischelli et al.	May 2007	A1
20070129760	Demarais et al.	Jun 2007	A1
20070129761	Demarais et al.	Jun 2007	A1
20070135875	Demarais et al.	Jun 2007	A1
20070149963	Matsukuma et al.	Jun 2007	A1
20070162109	Davila et al.	Jul 2007	A1
20070173805	Weinberg et al.	Jul 2007	A1
20070173899	Levin et al.	Jul 2007	A1
20070179496	Swoyer et al.	Aug 2007	A1
20070197891	Shachar et al.	Aug 2007	A1
20070203480	Mody et al.	Aug 2007	A1
20070207186	Scanlon et al.	Sep 2007	A1
20070208134	Hunter et al.	Sep 2007	A1
20070208210	Gelfand et al.	Sep 2007	A1
20070208256	Marilla	Sep 2007	A1
20070208301	Evard et al.	Sep 2007	A1
20070219576	Cangialosi	Sep 2007	A1
20070225781	Saadat et al.	Sep 2007	A1
20070233170	Gertner	Oct 2007	A1
20070239062	Chopra et al.	Oct 2007	A1
20070248639	Demopulos et al.	Oct 2007	A1
20070249703	Mewshaw et al.	Oct 2007	A1
20070254833	Hunter et al.	Nov 2007	A1
20070265687	Deem et al.	Nov 2007	A1
20070278103	Hoerr et al.	Dec 2007	A1
20070282302	Wachsman et al.	Dec 2007	A1
20070292411	Salcedo et al.	Dec 2007	A1
20070293782	Marino	Dec 2007	A1
20070299043	Hunter et al.	Dec 2007	A1
20080004673	Rossing et al.	Jan 2008	A1
20080009927	Vilims	Jan 2008	A1
20080015501	Gertner	Jan 2008	A1
20080021408	Jacobsen et al.	Jan 2008	A1
20080033049	Mewshaw	Feb 2008	A1
20080039746	Hissong et al.	Feb 2008	A1
20080039830	Munger et al.	Feb 2008	A1
20080051454	Wang	Feb 2008	A1
20080064957	Spence	Mar 2008	A1
20080071269	Hilario et al.	Mar 2008	A1
20080071306	Gertner	Mar 2008	A1
20080082109	Moll et al.	Apr 2008	A1
20080086072	Bonutti et al.	Apr 2008	A1
20080091193	Kauphusman et al.	Apr 2008	A1
20080097251	Babaev	Apr 2008	A1
20080097426	Root et al.	Apr 2008	A1
20080108867	Zhou	May 2008	A1
20080119879	Brenneman et al.	May 2008	A1
20080125772	Stone et al.	May 2008	A1
20080132450	Lee et al.	Jun 2008	A1
20080140002	Ramzipoor et al.	Jun 2008	A1
20080147002	Gertner	Jun 2008	A1
20080161662	Golijanin et al.	Jul 2008	A1
20080161717	Gertner	Jul 2008	A1
20080161801	Steinke et al.	Jul 2008	A1
20080171974	Lafontaine et al.	Jul 2008	A1
20080172035	Starksen et al.	Jul 2008	A1
20080172104	Kieval et al.	Jul 2008	A1
20080188912	Stone et al.	Aug 2008	A1
20080188913	Stone et al.	Aug 2008	A1
20080208162	Joshi	Aug 2008	A1
20080208169	Boyle et al.	Aug 2008	A1
20080213331	Gelfand et al.	Sep 2008	A1
20080215117	Gross	Sep 2008	A1
20080221448	Khuri-Yakub et al.	Sep 2008	A1
20080234790	Bayer et al.	Sep 2008	A1
20080243091	Humphreys et al.	Oct 2008	A1
20080245371	Gruber	Oct 2008	A1
20080249525	Lee et al.	Oct 2008	A1
20080249547	Dunn	Oct 2008	A1
20080255550	Bell	Oct 2008	A1
20080255642	Zarins et al.	Oct 2008	A1
20080262489	Steinke	Oct 2008	A1
20080275484	Gertner	Nov 2008	A1
20080281312	Werneth et al.	Nov 2008	A1
20080281347	Gertner	Nov 2008	A1
20080287918	Rosenman et al.	Nov 2008	A1
20080294037	Richter	Nov 2008	A1
20080300618	Gertner	Dec 2008	A1
20080312644	Fourkas et al.	Dec 2008	A1
20080312673	Viswanathan et al.	Dec 2008	A1
20080317818	Griffith et al.	Dec 2008	A1
20090018486	Goren et al.	Jan 2009	A1
20090018609	DiLorenzo	Jan 2009	A1
20090024194	Arcot-Krishnamurthy et al.	Jan 2009	A1
20090030312	Hadjicostis	Jan 2009	A1
20090036948	Levin et al.	Feb 2009	A1
20090043372	Northrop et al.	Feb 2009	A1
20090054082	Kim et al.	Feb 2009	A1
20090062873	Wu et al.	Mar 2009	A1
20090069671	Anderson	Mar 2009	A1
20090074828	Alexis et al.	Mar 2009	A1
20090076409	Wu et al.	Mar 2009	A1
20090088735	Abboud et al.	Apr 2009	A1
20090105631	Kieval	Apr 2009	A1
20090112202	Young	Apr 2009	A1
20090118620	Tgavalekos et al.	May 2009	A1
20090118726	Auth et al.	May 2009	A1
20090125099	Weber et al.	May 2009	A1
20090131798	Minar et al.	May 2009	A1
20090143640	Saadat et al.	Jun 2009	A1
20090156988	Ferren et al.	Jun 2009	A1
20090157057	Ferren et al.	Jun 2009	A1
20090157161	Desai et al.	Jun 2009	A1
20090171333	Hon	Jul 2009	A1
20090192558	Whitehurst et al.	Jul 2009	A1
20090198223	Thilwind et al.	Aug 2009	A1
20090203962	Miller et al.	Aug 2009	A1
20090203993	Mangat et al.	Aug 2009	A1
20090204170	Hastings et al.	Aug 2009	A1
20090210953	Moyer et al.	Aug 2009	A1
20090216317	Cromack et al.	Aug 2009	A1
20090221955	Babaev	Sep 2009	A1
20090226429	Salcedo et al.	Sep 2009	A1
20090240249	Chan et al.	Sep 2009	A1
20090247933	Maor et al.	Oct 2009	A1
20090247966	Gunn et al.	Oct 2009	A1
20090248012	Maor et al.	Oct 2009	A1
20090253974	Rahme	Oct 2009	A1
20090264755	Chen et al.	Oct 2009	A1
20090270850	Zhou et al.	Oct 2009	A1
20090281533	Ingle et al.	Nov 2009	A1
20090287137	Crowley	Nov 2009	A1
20090318749	Stolen et al.	Dec 2009	A1
20100009267	Chase et al.	Jan 2010	A1
20100030061	Canfield et al.	Feb 2010	A1
20100048983	Ball et al.	Feb 2010	A1
20100049099	Thapliyal et al.	Feb 2010	A1
20100049186	Ingle et al.	Feb 2010	A1
20100049188	Nelson et al.	Feb 2010	A1
20100049191	Habib et al.	Feb 2010	A1
20100049283	Johnson	Feb 2010	A1
20100069837	Rassat et al.	Mar 2010	A1
20100076299	Gustus et al.	Mar 2010	A1
20100076425	Carroux	Mar 2010	A1
20100087782	Ghaffari et al.	Apr 2010	A1
20100106005	Karczmar et al.	Apr 2010	A1
20100114244	Manda et al.	May 2010	A1
20100125239	Perry et al.	May 2010	A1
20100125268	Gustus et al.	May 2010	A1
20100130836	Malchano et al.	May 2010	A1
20100137860	Demarais et al.	Jun 2010	A1
20100137952	Demarais et al.	Jun 2010	A1
20100160903	Krespi	Jun 2010	A1
20100160906	Jarrard	Jun 2010	A1
20100168624	Sliwa	Jul 2010	A1
20100168731	Wu et al.	Jul 2010	A1
20100168739	Wu et al.	Jul 2010	A1
20100174282	Demarais et al.	Jul 2010	A1
20100191112	Demarais et al.	Jul 2010	A1
20100191232	Boveda	Jul 2010	A1
20100204560	Salahieh et al.	Aug 2010	A1
20100217162	Hissong et al.	Aug 2010	A1
20100222786	Kassab	Sep 2010	A1
20100222851	Deem et al.	Sep 2010	A1
20100222854	Demarais et al.	Sep 2010	A1
20100228122	Keenan et al.	Sep 2010	A1
20100249604	Hastings et al.	Sep 2010	A1
20100249702	Magana et al.	Sep 2010	A1
20100249773	Clark et al.	Sep 2010	A1
20100256616	Katoh et al.	Oct 2010	A1
20100268217	Habib	Oct 2010	A1
20100268307	Demarais et al.	Oct 2010	A1
20100284927	Lu et al.	Nov 2010	A1
20100286684	Hata et al.	Nov 2010	A1
20100298821	Garbagnati	Nov 2010	A1
20100305036	Barnes et al.	Dec 2010	A1
20100312141	Keast et al.	Dec 2010	A1
20100324472	Wulfman	Dec 2010	A1
20110009750	Taylor et al.	Jan 2011	A1
20110021976	Li et al.	Jan 2011	A1
20110034832	Cioanta et al.	Feb 2011	A1
20110040324	McCarthy et al.	Feb 2011	A1
20110044942	Puri et al.	Feb 2011	A1
20110060324	Wu et al.	Mar 2011	A1
20110071400	Hastings et al.	Mar 2011	A1
20110071401	Hastings et al.	Mar 2011	A1
20110077498	McDaniel	Mar 2011	A1
20110092781	Gertner	Apr 2011	A1
20110092880	Gertner	Apr 2011	A1
20110104061	Seward	May 2011	A1
20110112400	Emery et al.	May 2011	A1
20110118598	Gertner	May 2011	A1
20110118600	Gertner	May 2011	A1
20110118726	De La Rama et al.	May 2011	A1
20110130708	Perry et al.	Jun 2011	A1
20110137155	Weber et al.	Jun 2011	A1
20110144479	Hastings et al.	Jun 2011	A1
20110146673	Keast et al.	Jun 2011	A1
20110166499	Demarais et al.	Jul 2011	A1
20110178403	Weng et al.	Jul 2011	A1
20110178570	Demarais	Jul 2011	A1
20110200171	Beetel et al.	Aug 2011	A1
20110202098	Demarais et al.	Aug 2011	A1
20110207758	Sobotka et al.	Aug 2011	A1
20110208096	Demarais et al.	Aug 2011	A1
20110257523	Hastings et al.	Oct 2011	A1
20110257564	Demarais et al.	Oct 2011	A1
20110257622	Salahieh et al.	Oct 2011	A1
20110257641	Hastings et al.	Oct 2011	A1
20110257642	Griggs, III	Oct 2011	A1
20110263921	Vrba et al.	Oct 2011	A1
20110264011	Wu et al.	Oct 2011	A1
20110264075	Leung et al.	Oct 2011	A1
20110264086	Ingle	Oct 2011	A1
20110264116	Kocur et al.	Oct 2011	A1
20110270238	Rizq et al.	Nov 2011	A1
20110306851	Wang	Dec 2011	A1
20110307034	Hastings et al.	Dec 2011	A1
20110319809	Smith	Dec 2011	A1
20120029496	Smith	Feb 2012	A1
20120029500	Jenson	Feb 2012	A1
20120029505	Jenson	Feb 2012	A1
20120029509	Smith	Feb 2012	A1
20120029510	Haverkost	Feb 2012	A1
20120029511	Smith et al.	Feb 2012	A1
20120029512	Willard et al.	Feb 2012	A1
20120029513	Smith et al.	Feb 2012	A1
20120059241	Hastings et al.	Mar 2012	A1
20120059286	Hastings et al.	Mar 2012	A1
20120065506	Smith	Mar 2012	A1
20120065554	Pikus	Mar 2012	A1
20120095461	Herscher et al.	Apr 2012	A1
20120101413	Beetel et al.	Apr 2012	A1
20120101490	Smith	Apr 2012	A1
20120101538	Ballakur et al.	Apr 2012	A1
20120109021	Hastings et al.	May 2012	A1
20120116382	Ku et al.	May 2012	A1
20120116383	Mauch et al.	May 2012	A1
20120116392	Willard	May 2012	A1
20120116438	Salahieh et al.	May 2012	A1
20120116486	Naga et al.	May 2012	A1
20120123243	Hastings	May 2012	A1
20120123258	Willard	May 2012	A1
20120123261	Jenson et al.	May 2012	A1
20120123303	Sogard et al.	May 2012	A1
20120123406	Edmunds et al.	May 2012	A1
20120130289	Demarais et al.	May 2012	A1
20120130345	Levin et al.	May 2012	A1
20120130359	Turovskiy	May 2012	A1
20120130360	Buckley et al.	May 2012	A1
20120130362	Hastings et al.	May 2012	A1
20120130368	Jenson	May 2012	A1
20120130458	Ryba et al.	May 2012	A1
20120136344	Buckley et al.	May 2012	A1
20120136349	Hastings	May 2012	A1
20120136350	Goshgarian et al.	May 2012	A1
20120136417	Buckley et al.	May 2012	A1
20120136418	Buckley et al.	May 2012	A1
20120143181	Demarais et al.	Jun 2012	A1
20120143293	Mauch et al.	Jun 2012	A1
20120143294	Clark et al.	Jun 2012	A1
20120150267	Buckley et al.	Jun 2012	A1
20120157986	Stone et al.	Jun 2012	A1
20120157987	Steinke et al.	Jun 2012	A1
20120157988	Stone et al.	Jun 2012	A1
20120157989	Stone et al.	Jun 2012	A1
20120157992	Smith et al.	Jun 2012	A1
20120157993	Jenson et al.	Jun 2012	A1
20120158101	Stone et al.	Jun 2012	A1
20120158104	Huynh et al.	Jun 2012	A1
20120172837	Demarais et al.	Jul 2012	A1
20120172870	Jenson et al.	Jul 2012	A1
20120184952	Jenson et al.	Jul 2012	A1
20120197198	Demarais et al.	Aug 2012	A1
20120197252	Deem et al.	Aug 2012	A1
20120232409	Stahmann et al.	Sep 2012	A1
20120265066	Crow et al.	Oct 2012	A1
20120265198	Crow et al.	Oct 2012	A1
20130012844	Demarais et al.	Jan 2013	A1
20130012866	Deem et al.	Jan 2013	A1
20130012867	Demarais et al.	Jan 2013	A1
20130013024	Levin et al.	Jan 2013	A1
20130023865	Steinke et al.	Jan 2013	A1
20130035681	Subramanaim et al.	Feb 2013	A1
20130066316	Steinke et al.	Mar 2013	A1
20130085489	Fain et al.	Apr 2013	A1
20130090563	Weber	Apr 2013	A1
20130090578	Smith et al.	Apr 2013	A1
20130090647	Smith	Apr 2013	A1
20130090649	Smith et al.	Apr 2013	A1
20130090650	Jenson et al.	Apr 2013	A1
20130090651	Smith	Apr 2013	A1
20130090652	Jenson	Apr 2013	A1
20130096550	Hill	Apr 2013	A1
20130096553	Hill et al.	Apr 2013	A1
20130096554	Groff et al.	Apr 2013	A1
20130096604	Hanson et al.	Apr 2013	A1
20130110106	Richardson	May 2013	A1
20130116687	Willard	May 2013	A1
20130165764	Scheuermann et al.	Jun 2013	A1
20130165844	Shuros et al.	Jun 2013	A1
20130165916	Mathur et al.	Jun 2013	A1
20130165917	Mathur et al.	Jun 2013	A1
20130165920	Weber et al.	Jun 2013	A1
20130165923	Mathur et al.	Jun 2013	A1
20130165924	Mathur et al.	Jun 2013	A1
20130165925	Mathur et al.	Jun 2013	A1
20130165926	Mathur et al.	Jun 2013	A1
20130165990	Mathur et al.	Jun 2013	A1
20130172815	Perry et al.	Jul 2013	A1
20130172872	Subramaniam et al.	Jul 2013	A1
20130172877	Subramaniam et al.	Jul 2013	A1
20130172878	Smith	Jul 2013	A1
20130172879	Sutermeister	Jul 2013	A1
20130172880	Willard	Jul 2013	A1
20130172881	Hill et al.	Jul 2013	A1

Foreign Referenced Citations (162)

Number	Date	Country
2384866	Apr 2001	CA
10038737	Feb 2002	DE
102005041601	Apr 2007	DE
102008048616	Apr 2010	DE
0558297	Sep 1993	EP
0647435	Apr 1995	EP
0634910	Aug 1997	EP
0868884	Oct 1998	EP
1005838	Jun 2000	EP
1053720	Nov 2000	EP
1064886	Jan 2001	EP
1180004	Feb 2002	EP
1181895	Feb 2002	EP
1264613	Dec 2002	EP
1297795	Apr 2003	EP
1286625	May 2003	EP
1332724	Aug 2003	EP
1335677	Aug 2003	EP
0866675	Oct 2003	EP
1433448	Jun 2004	EP
1442719	Aug 2004	EP
1547537	Jun 2005	EP
1634542	Mar 2006	EP
1698296	Sep 2006	EP
1709922	Oct 2006	EP
1874211	Jan 2008	EP
1906853	Apr 2008	EP
1946712	Jul 2008	EP
1961394	Aug 2008	EP
1715798	Apr 2009	EP
1620156	Jul 2009	EP
2076193	Jul 2009	EP
2091455	Aug 2009	EP
2197533	Jun 2010	EP
2208506	Jul 2010	EP
1579889	Aug 2010	EP
2241279	Oct 2010	EP
2092957	Jan 2011	EP
2239859	Jun 2011	EP
2329859	Jun 2011	EP
2349044	Aug 2011	EP
2027882	Oct 2011	EP
2378956	Oct 2011	EP
2037840	Dec 2011	EP
2204134	Apr 2012	EP
2320821	Oct 2012	EP
2313062	Nov 1997	GB
2453601	Apr 2009	GB
2456301	Jul 2009	GB
7213621	Aug 1995	JP
7313603	Dec 1995	JP
2003510126	Mar 2003	JP
9103207	Mar 1991	WO
9117731	Nov 1991	WO
9222239	Dec 1992	WO
9320747	Oct 1993	WO
9320770	Oct 1993	WO
9418896	Sep 1994	WO
9428809	Dec 1994	WO
9501751	Jan 1995	WO
9531142	Nov 1995	WO
9634559	Nov 1996	WO
9703604	Feb 1997	WO
9717104	May 1997	WO
9720510	Jun 1997	WO
9732532	Sep 1997	WO
9740760	Nov 1997	WO
9745156	Dec 1997	WO
9745157	Dec 1997	WO
9818393	May 1998	WO
9829030	Jul 1998	WO
9834565	Aug 1998	WO
9835638	Aug 1998	WO
9840023	Sep 1998	WO
9858588	Dec 1998	WO
9900060	Jan 1999	WO
9916370	Apr 1999	WO
9921608	May 1999	WO
9934741	Jul 1999	WO
9944522	Sep 1999	WO
0001313	Jan 2000	WO
0010475	Mar 2000	WO
0047118	Aug 2000	WO
0051513	Sep 2000	WO
0059394	Oct 2000	WO
0062727	Oct 2000	WO
0064387	Nov 2000	WO
0069376	Nov 2000	WO
0072909	Dec 2000	WO
0122897	Apr 2001	WO
0137746	May 2001	WO
0174255	Oct 2001	WO
0137723	Nov 2001	WO
0187154	Nov 2001	WO
0187172	Nov 2001	WO
0195820	Dec 2001	WO
0215807	Feb 2002	WO
0228475	Apr 2002	WO
0239915	May 2002	WO
02058549	Aug 2002	WO
02080766	Oct 2002	WO
02087679	Nov 2002	WO
02089686	Nov 2002	WO
02089871	Nov 2002	WO
03026525	Apr 2003	WO
03077781	Sep 2003	WO
2004047659	Jun 2004	WO
2004049976	Jun 2004	WO
2004064606	Aug 2004	WO
2004069300	Aug 2004	WO
2004076146	Sep 2004	WO
2004098694	Nov 2004	WO
2004100813	Nov 2004	WO
2004105807	Dec 2004	WO
2004110258	Dec 2004	WO
2005007000	Jan 2005	WO
2005037070	Apr 2005	WO
2005041748	May 2005	WO
2005074829	Aug 2005	WO
2006041881	Apr 2006	WO
2006105121	Oct 2006	WO
2006116198	Nov 2006	WO
2007011634	Jan 2007	WO
2007014063	Feb 2007	WO
2007047870	Apr 2007	WO
2007113865	Oct 2007	WO
2007135431	Nov 2007	WO
2007146215	Dec 2007	WO
2008003058	Jan 2008	WO
2008009972	Jan 2008	WO
2008010150	Jan 2008	WO
2008014465	Jan 2008	WO
2008036281	Mar 2008	WO
2008049084	Apr 2008	WO
2008061152	May 2008	WO
2008102363	Aug 2008	WO
2009036471	Mar 2009	WO
2009082635	Jul 2009	WO
2009088678	Jul 2009	WO
2009113064	Sep 2009	WO
2009121017	Oct 2009	WO
2009137819	Nov 2009	WO
2010042653	Apr 2010	WO
2010048007	Apr 2010	WO
2010056771	May 2010	WO
2010057043	May 2010	WO
2010067360	Jun 2010	WO
2010070766	Jun 2010	WO
2010099207	Sep 2010	WO
2010102310	Sep 2010	WO
2010120944	Oct 2010	WO
2010134503	Nov 2010	WO
2011005901	Jan 2011	WO
2011053757	May 2011	WO
2011053772	May 2011	WO
2011055143	May 2011	WO
2011060339	May 2011	WO
2011091069	Jul 2011	WO
2011126580	Oct 2011	WO
2011130534	Oct 2011	WO
2012019156	Feb 2012	WO
2013049601	Apr 2013	WO

Non-Patent Literature Citations (70)

Entry
CardioVascular Technologies Inc., “Heated Balloon Device Technology,” 11 pages, 2008.
Strategic Business Development, Inc., “Thermal and Disruptive Angioplasty: A Physician's Guide,” 8 pages, 1990.
Zhang et al., “Non-contact Radio-Frequency Ablation for Obtaining Deeper Lesions,” IEEE Transaction on Biomedical Engineering, vol. 50, No. 2, 6 pages, Feb. 2003.
Lazebnik et al., “Tissue Strain Analytics Virtual Touch Tissue Imaging and Qualification,” Siemens Whitepaper, Oct. 2008, 7 pages.
Zhou et al., “Mechanism Research of Cryoanalgesia,” Forefront Publishing Group, 1995.
Florete, “Cryoblative Procedure for Back Pain,” Jacksonville Medicine, Oct. 1998, 10 pages.
Stevenson, “Irrigated RF Ablation: Power Titration and Fluid Management for Optimal Safety Efficacy,” 2005, 4 pages.
Giliatt et al., “The Cause of Nerve Damage in Acute Compression,” Trans Am Neurol Assoc, 1974: 99; 71-4.
Baun, “Interaction with Soft Tissue,” Principles of General & Vascular Sonography, Chapter 2, pp. 23-24, Before Mar. 2012.
Blue Cross Blue Shield Medicaly Policy, “Surgery Section—MRI-Guided Focused Ultrasound (MRgFUS) for the Treatment of Uterine Fibroids and Other Tumors,” 2005, 5 pages.
Gentry et al., “Combines 3D Intracardiac Echo and Ultrasound Ablation,” Medical Imaging 2003: Ultrasonic and Signal Processing, vol. 5035, 2003, pp. 166-173.
Lafon et al., “Optmizing the Shape of Ultrasound Transducers for Interstitial Thermal Ablations,” MEd Phys. Mar. 2002; 29(3): 290-7 (abstract only).
G. Ter Haar, “Ultrasound Focal Beam Surgery,” Ultrasound in Med. & Biol., 1995, vol. 21, No. 9, pp. 1089-1100.
Seip et al., “Transurethral High Intensity Focused Ultrasound: Catheter Based Prototypes and Experimental Results,” IEEE Ultrasonics Symposium Proceeding, 2000, 4 pages.
Toytman et al., “Tissue Dissection with Ultrafast Laser Using Extended and Multiple Foci,” SPIE Proceeding, Optical Interactions with Tissues and Cells XXI, vol. 7562, 2010, 10 pages.
Zhoue et al., “Non-Thermal Ablation of Rabbit Liver VX2 Tumore by Pulsed High Intensity Focused Ultrasound Contrast Agent: Pathological Characteristics,” World Journal of Gastroenterology, vol. 14(43), Nov. 21, 2008, pp. 6743-6747.
US 8,398,630, 3/2013, Demarais et al (withdrawn).
Van Den Berg, “Light echoes image the human body,” OLE, Oct. 2001, p. 35-37.
“IntraLuminal: Products,” IntraLuminal Therapeutics, Inc., 2003, p. 1-9.
“Laser Catheter to Aid Coronary Surgery,” TechTalk: MIT, Jan. 9, 1991, p. 1-4.
“Optical Coherence Tomography: LightLab Imaging Starts US Cardiology Clinical Investigations,” LightLab Imaging Technology, 2002.
“Optical Coherence Tomography: LightLab Sees Bright Prospects for Cardiac Application of OCT Technology,” LightLab Imaging Technology, 2001, vol. 27, No. 35.
“Products—Functional Measurement,” VOLCANO Functional Measurement Products US, Mar. 24, 2003, p. 1-2.
Brown et al., “Radiofrequency capacitive heaters: the effect of coupling medium resistivity on power absorption along a mouse leg,” Physics in Medicine and Biology, 1993, p. 1-12, vol. 38.
Carrington, “Future of CVI: It's all about plaque: Identification of vulnerable lesions, not ‘rusty pipes,’ could become cornerstone of preventive cardiology,” Diagnostic Imaging, 2001, p. 1-8.
Chen et al., “Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo,” EuroIntervention, 2013, p. 1-8.
Cimino, “Preventing plaque attack,” Mass High Tech, 2001, p. 1-2.
Dahm et al., “Relation of Degree of Laser Debulking of In-Stent Restenosis as a Predictor of Restenosis Rate,” The American Journal of Cardiology, 2002, p. 68-70, vol. 90.
De Korte et al., “Characterization of Plaque Components With Intravascular Ultrasound Elastography in Human Femoral and Coronary Arteries In Vitro,” Circulation, Aug. 8, 2000, p. 617-623.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook,” Oct. 1986, p. 1-2, Fourth Edition.
Durney et al., “Radiofrequency Radiation Dosimetry Handbook: Contents,” Oct. 1986, p. 1-5, Fourth Edition.
Fournier-Desseux et al., “Assessment of 1-lead and 2-lead electrode patterns in electrical impedance endotomography,” Physiological Measurement, 2005, p. 337-349. Vo. 26, Institute of Physics Publishing.
Fram et al., “Feasibility of Radiofrequency Powered, Thermal Balloon Ablation of Atrioventricular Bypass Tracts via the Coronary Sinus: In Vivo Canine Studies,” PACE, Aug. 1995, p. 1518-1530, vol. 18.
Fram et al., “Low Pressure Radiofrequency Balloon Angioplasty: Evaluation in Porcine Peripheral Arteries,” JACC, 1993, p. 1512-1521, vol. 21, No. 6, American College of Cardiology.
Fujimori et al., “Significant Prevention of In-Stent Restenosis by Evans Blue in Patients with Acute Myocardial Infarction,” American Heart Association, 2002.
Fujita et al., “Sarpogrelate, An Antagonist of 5-HT(2A) Receptor, Treatment Reduces Restenosis After Coronary Stenting,” American Heart Association, 2002.
Gabriel, “Appendix A: Experimental Data,” 1999, p. 1-21.
Gregory et al., “Liquid Core Light Guide for Laser Angioplasty,” The Journal of Quantum Electronics, Dec. 1990, p. 2289-2296, vol. 26, No. 12.
Kaplan et al., “Healing after Arterial Dilatation with Radiofrequency Thermal and Nonthermal Balloon Angioplasty Sytems,” Journal of Investigative Surgery, 1993, p. 33-52, vol. 6.
Kolata, “New Studies Question Value of Opening Arteries,” The New York Times, Mar. 21, 2004, p. 1-5.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, Aug. 1997, p. 439-446, vol. 16, No. 4.
Kurtz et al., “Lamellar Refractive Surgery with Scanned Intrastromal Picosecond and Femtosecond Laser Pulses in Animal Eyes,” Journal of Refractive Surgery, Sep./Oct. 1998, p. 541-548.
Lee et al., “Thermal Compression and Molding of Atherosclerotic Vascular Tissue With Use of Radiofrequency Energy: Implications for Radiofrequency Balloon Angioplasty,” JACC, 1989, p. 1167-1175, vol. 13, No. 5, American College of Cardiology.
Lima et al., “Efficacy and Safety of Oral Sirolimus to Treat and Prevent In-Stent Restenosis: A Pilot Study Results,” American Heart Association, 2002, p. 2929.
Lima et al., “Systemic Immunosuppression Inhibits In-Stent Coronary Intimal Proliferation in Renal Transplant Patients,” American Heart Association, 2002, p. 2928.
Morice et al., “A Randomized Comparison of a Sirolimus-Eluting Stent With a Standard Stent for Coronary Revascularization,” The New England Journal of Medicine, Jun. 6, 2012, p. 1773-1780, vol. 346, No. 23.
Muller-Leisse et al., “Effectiveness and Safety of Ultrasonic Atherosclerotic Plaque Ablation: In Vitro Investigation,” CardioVascular and Interventional Radiology, 1993, p. 303-307, vol. 16.
Nair et al., “Regularized Autoregressive Analysis of Intravascular Ultrasound Backscatter: Improvement in Spatial Accuracy of Tissue Maps,” IEEE Transactions on Ultrasonics, Apr. 2004, p. 420-431, vol. 51, No. 4.
Resar et al., “Endoluminal Sealing of Vascular Wall Disruptions With Radiofrequency-Heated Balloon Angioplasty,” Catheterization and Cardiovascular Diagnosis, 1993, p. 161-167, vol. 29.
Romer et al., “Histopathology of Human Coronary Atherosclerosis by Quantifying Its Chemical Composition With Raman Spectroscopy,” Circulation, 1998, p. 878-885, vol. 97.
Schauerte et al., “Catheter Ablation of Cardiac Autonomic Nerves for Prevention of Vagal Atrial Fibrillation,” Circulation, 2000, p. 2774-2780, vol. 102.
Scheller et al., “Intracoronary Paclitaxel Added to Contrast Media Inhibits In-Stent Restenosis of Porcine Coronary Arteries,” American Heart Association, 2002, p. 2227.
Scheller et al., “Potential solutions to the current problem: coated balloon,” EuroIntervention, 2008, p. C63-C66, vol. 4 (Supplement C).
Shaffer, “Scientific basis of laser energy,” Clinics in Sports Medicine, 2002, p. 585-598, vol. 21.
Shmatukha et al., “MRI temperature mapping during thermal balloon angioplasty,” Physics in Medicine and Biology, 2006, p. N163-N171, vol. 51.
Slager et al., “Vaporization of Atherosclerotic Plaques by Spark Erosion,” J Am Coll Cardiol, 1985, p. 21-25.
Stiles et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEEE Transactions on Biomedical Engineering, Jul. 2003, p. 916-921, vol. 50, No. 7.
Suselbeck et al., “In vivo intravascular electric impedance spectroscopy using a new catheter with integrated microelectrodes,” Basic Res Cardiol, 2005, p. 28-34, vol. 100.
Suselbeck et al., “Intravascular electric impedance spectroscopy of atherosclerotic lesions using a new impedance catheter system,” Basic Res Cardiol, 2005, p. 446-452, vol. 100.
Tepe et al., “Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the Leg,” The New England Journal of Medicine, 2008, p. 689-699, vol. 358.
Brown et al., “Observations on the Shrink Temperature of Collagen and Its Variations with Age and Disease,” Ann Rheum Dis., vol. 17, No. 2, pp. 196-208, Jun. 1, 1958.
Gabriel C, et al., Compilation of the Dielectric Properties of Body Tissues at RF and Microwave Frequencies (with table of contents), Jun. 1996, 17 pages, Armstrong Laboratory (AFMC) Occupational and Environmental Health Directorate Radiofrequency Radiation Division, USAF School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooks Air Force Base, http://www.brooks.af.mil/AFRL/HED/hedr/reports/dielectric/Report/Report.html.
Gabriel, “Appendix C: Modeling the frequency dependence of the dielectric properties to a 4 dispersions spectrum,” p. 1-49, Nov. 6, 1997.
Han et al., “Third-Generation Cryosurgery for Primary and Recurrent Prostate Caner,” BJU International, vol. 93, pp. 14-18, 2004.
Omura et al., “A Mild Acute Compression Induces Neurapraxia in Rat Sciatic Nerve,” The International Journal of Neuroscience, vol. 114 (12), pp. 1561-1572, Dec. 2004.
“Optical Coherence Tomography: Advantages of OCT,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Image Gallery Cardiovascular Procedures,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: What is OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
“Optical Coherence Tomography: Why Use OCT?,” LightLab Imaging Technology, printed Sep. 3, 2003.
Popma et al., “Percutaneous Coronary and Valvular Intervention,” Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th edition, p. 1364-1405, 2005.

Related Publications (1)

	Number	Date	Country
	20130066316 A1	Mar 2013	US

Provisional Applications (1)

	Number	Date	Country
	60502515	Sep 2003	US

Divisions (1)

	Number	Date	Country
Parent	10938138	Sep 2004	US
Child	11864779		US

Continuations (2)

	Number	Date	Country
Parent	13403920	Feb 2012	US
Child	13671474		US
Parent	11864779	Sep 2007	US
Child	13403920		US

Selectable eccentric remodeling and/or ablation

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

CPC

Field of Search

CPC

International Classifications

Term Extension

Abstract